ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each Exchange on which Registered
|
|
|
|
|
|
|
|
Accelerated filer
|
☐
|
|
Non-accelerated filer ☐
|
Smaller reporting company
|
|
|
|
Emerging growth company
|
|
Class
|
|
Number of Shares Outstanding
|
Class A Common Stock, $0.0001 par value
|
|
|
Class B Common Stock, $0.0001 par value
|
|
|
PART I
|
||
Item 1
|
4
|
|
Item 1A
|
19
|
|
Item 2
|
52
|
|
Item 3
|
52
|
|
PART II
|
||
Item 5
|
53
|
|
Item 7
|
55 | |
Item 7A
|
78
|
|
Item 8
|
80 | |
Item 9A
|
124
|
|
PART III
|
||
Item 10
|
128 | |
Item 11
|
128
|
|
Item 12
|
128
|
|
Item 13
|
128
|
|
Item 14
|
128
|
|
PART IV
|
||
Item 15
|
129
|
|
134
|
Item 1. |
Business
|
● |
Space Alternated Phase Shift, or SAPS, technology for flat and patterned (deep via or deep trench with stronger structure) wafer surfaces. SAPS technology employs
alternating phases of megasonic waves to deliver megasonic energy in a highly uniform manner on a microscopic level. We have shown SAPS technology to be more effective than conventional megasonic and jet spray technologies in removing
random defects across an entire wafer, with increasing relative effectiveness at more advanced production nodes.
|
● |
Timely Energized Bubble Oscillation, or TEBO, technology for patterned wafer surfaces at advanced process nodes. TEBO technology has been developed to provide
effective, damage-free cleaning for 2D and 3D patterned wafers with fine feature sizes. We have demonstrated the damage-free cleaning capabilities of TEBO technology on patterned wafers for feature nodes as small as 1xnm (16 to 19
nanometers, or nm), and we have shown TEBO technology can be applied in manufacturing processes for patterned chips with 3D architectures having aspect ratios as high as 60‑to‑1.
|
● |
Tahoe technology for cost and environmental savings. Tahoe technology delivers high cleaning performance using significantly less sulfuric acid and hydrogen peroxide
than is typically consumed by conventional high-temperature single-wafer cleaning tools.
|
● |
ECP technology for advanced
metal plating. Our Ultra ECP ap, or Advanced Packaging, technology was developed for back-end assembly processes to deliver a more uniform metal layer at the notch area of wafers prior to packaging. Our Ultra ECP map, or
Multi-Anode Partial Plating, technology was developed for front-end wafer fabrication processes to deliver advanced electrochemical copper plating for copper interconnect applications. Ultra ECP map offers improved gap-filling
performance for ultra-thin seed layer applications, which is critical for advanced nodes at 28nm, 14nm and beyond.
|
● |
Post CMP: Chemical mechanical planarization, or CMP, uses an abrasive chemical slurry following other fabrication processes, such as deposition and etching, in order
to achieve a smooth wafer surface in preparation for subsequent processing steps. SAPS technology can be applied following each CMP process to remove residual random defects deposited or formed during CMP.
|
● |
Post Hard Mask Deposition: As part of the photolithographical patterning process, a mask is applied with each deposition of a material layer to prevent etching of
material intended to be retained. Hard masks have been developed to etch high aspect-ratio features of advanced chips that traditional masks cannot tolerate. SAPS technology can be applied following each deposition step involving hard masks
that use nitride, oxide or carbon based materials to achieve higher etch selectivity and resolution.
|
● |
Post Contact/Via Etch: Wet etching processes are commonly used to create patterns of high-density contacts and vias. SAPS technology can be applied after each such
etching process to remove random defects that could otherwise lead to electrical shorts.
|
● |
Pre Barrier Metal Deposition: Copper wiring requires metal diffusion barriers at the top of via holes to prevent electrical leakage. SAPS technology can be applied
prior to deposition of barrier metal to remove residual oxidized copper, which otherwise would adhere poorly to the barrier and impair performance.
|
● compact design, with footprint of 2.65m x 4.10m x 2.85m (WxDxH), requiring limited clean room floor space;
|
|
● up to 8 chambers, providing throughput of up to 225 wafers per hour;
|
|
● double-sided cleaning capability, with up to 5 cleaning chemicals for process flexibility;
|
|
● 2-chemical recycling capability for reduced chemical consumption;
|
|
● image wafer detection method for lowering wafer breakage rates; and
|
|
● chemical delivery module for delivery of dilute hydrofluoric acid, RCA SC-1 solution, functional de-ionized water and carbon dioxide to each of
the chambers.
|
● compact design, with footprint of 2.55m x 5.1m x 2.85m (WxDxH), requiring limited clean room floor space;
|
|
● up to 12 chambers, providing throughput of up to 375 wafers per hour;
|
|
● chemical supply system integrated into mainframe;
|
|
● inline mixing method replaces tank auto-changing, reducing process time; and
|
|
● improved drying technology using hot isopropyl alcohol and de-ionized water.
|
● |
Memory Chips: We estimate that TEBO technology can be applied in as many as 50 steps in the fabrication of a DRAM chip, consisting of up to 10 steps in cleaning ISO
structures, 20 steps in cleaning buried gates, and 20 steps in cleaning high aspect-ratio storage nodes and stacked films.
|
● |
Logic Chips: In the fabrication process for a logic chip with a FinFET structure, we estimate that TEBO technology can be used in 15 or more cleaning steps.
|
● an equipment front-end module, or EFEM, which moves wafers from chamber to chamber;
● one or more chamber modules, each equipped with a TEBO megasonic generator system;
● an electrical module to provide power for the tool; and
● a chemical delivery module.
|
|
Ultra C TEBO II (released in 2016). Highlights of our Ultra C TEBO II equipment include:
|
|
● compact design, with footprint of 2.25m x 2.25m x 2.85m (WxDxH);
● up to 8 chambers with an upgraded transport system and optimized robotic scheduler, providing throughput of up to 300 wafers per hour;
● EFEM module consisting of 4 load ports, transfer robot and 1 process robot; and
● focus on dilute chemicals contributes to environmental sustainability and lower cost of ownership.
|
|
Ultra C TEBO V (released in 2016). Highlights of our Ultra C TEBO V equipment include:
|
|
● footprint of 2.45m x 5.30m x 2.85m (WxDxH);
● up to 12 chamber modules, providing throughput of up to 300 wafers per hour;
● EFEM module consisting of 4 load ports, 1 transfer robot and 1 process robot; and
● chemical delivery module for delivery of isopropyl alcohol, dilute hydrofluoric acid, RCA SC-1 solution, functional de-ionized water and carbon
dioxide to each of the chambers.
|
● |
new cleaning steps for Ultra C SAPS cleaners for application in logic chips and for DRAM, and 3D NAND technologies;
|
● |
new cleaning steps for Ultra C TEBO cleaners for FinFET in logic chips, gates in DRAM, and deep vias in 3D NAND technologies;
|
● |
new cleaning steps for Ultra Tahoe cleaners for application in logic chips and for DRAM and 3D NAND technologies;
|
● |
new dry technologies such as supercritical CO2 dry and advanced IPA dry for DRAM, and logic technologies;
|
● |
new hardware, including new system platforms, new and additional chamber structures and new chemical blending systems; and
|
● |
new software to integrate new functionalities to improve tool performance.
|
● |
better established credibility and market reputations, longer operating histories, and broader product offerings;
|
● |
significantly greater financial, technical, marketing and other resources, which may allow them to pursue design, development, manufacturing, sales, marketing, distribution and service support of their
products;
|
● |
more extensive customer and partner relationships, which may position them to identify and respond more successfully to market developments and changes in customer demands; and
|
● |
multiple product offerings, which may enable them to offer bundled discounts for customers purchasing multiple products or other incentives that we cannot match or offer.
|
● |
performance of products, including particle removal efficiency, rate of damage to wafer structures, high temperature chemistry, throughput, tool uptime and reliability, safety, chemical waste treatment, and
environmental impact;
|
● |
gap filling capability, the deposited film thickness uniformity within wafer and wafer to wafer, particle generated on the wafer during the
processes;
|
● |
service support capability and spare parts delivery time; innovation and development of functionality and features that are must-haves for advanced fabrication nodes;
|
● |
ability to anticipate customer requirements, especially for advanced process nodes of less than 45nm; ability to identify new process applications;
|
● |
brand recognition and reputation; and
|
● |
skill and capability of personnel, including design engineers, manufacturing engineers and technicians, application engineers, and service engineers.
|
Item 1A. |
Risk Factors
|
● |
our potential future needs for additional capital that may not be available at all or on terms acceptable to us;
|
● |
the cyclicality in the semiconductor industry that may lead to substantial variations in demand for our products,
|
● |
industry manufacturers of integrated circuits, or chips, adopting our Space Alternated Phase Shift or SAPS, Timely Energized Bubble Oscillation or TEBO, Tahoe and Electro-Chemical Plating or ECP, and furnace
and other capital equipment, or tools;
|
● |
our SAPS, TEBO, Tahoe, ECP, furnace and other technologies not achieving widespread market acceptance;
|
● |
our ability to continue to enhance our existing single-wafer wet cleaning tools and identifying and entering new product markets;
|
● |
our ability to establish and maintain a reputation for credibility and product quality;
|
● |
our ability to expand our customer base;
|
● |
our dependence on a small number of customers for a substantial portion of our revenue;
|
● |
our long and unpredictable sales cycle, including our incurrence of significant expenses long before we can recognize revenue from new products, if at all;
|
● |
difficulties in forecasting demand for our tools;
|
● |
our reliance on third parties to manufacture significant portions of our tools and our ability to manage our relationships with these parties;
|
● |
any shortage of components or subassemblies, which could result in delayed delivery of products to us or in increased costs to us;
|
● |
our dependence on a limited number of suppliers, including single source suppliers, for critical components and subassemblies;
|
● |
our dependence on our Chief Executive Officer and President and other senior management and key employees;
|
● |
changes in government trade policies that could limit the demand for our tools and increase the cost of our tools;
|
● |
regulatory action limiting our ability to sell our tools to Chinese customers;
|
● |
changes in political and economic policies with respect to the People’s Republic of China or PRC;
|
● |
the PRC’s currency exchange control and government restrictions on investment repatriation may impact our ability to transfer funds outside of the PRC;
|
● |
the inability of the U.S. Public Company Accounting Oversight Board, or PCAOB, to inspect our auditor, as a registered public accounting firm operating in the PRC and the adoption of proposed legislation
related to companies operating in “restrictive markets”;
|
● |
our ability to implement our strategy to expand our PRC operations;
|
● |
our ability to achieve the results contemplated by our business strategy and our strategy for growth in the PRC and expectations related to the STAR Market listing;
|
● |
the effect of ACM Shanghai’s status as a publicly traded company that is controlled, but less than wholly owned, by ACM Research;
|
● |
our ability to manage potentially inconsistent accounting and disclosure requirements of ACM Research and ACM Shanghai as a result of the STAR Market Listing;
|
● |
our ability to protect our intellectual property, including in the PRC;
|
● |
breaches of our cybersecurity systems;
|
● |
impacts on our global supply chain due to the COVID‑19 pandemic, and our ability to successfully manage the demand, supply, and operational challenges associated with the global semiconductor shortage;
|
● |
the impact of the COVID‑19 pandemic on our currently planned projects and investments in the PRC, including the STAR IPO;
|
● |
the volatility in the market price of Class A common stock;
|
● |
manipulative short sellers of our stock, which may drive down the market price of our Class A common stock and could result in litigation;
|
● |
the difficulty to predict the effect of the STAR Listing and STAR IPO on the Class A common stock;
|
● |
the dual class structure of Class A common stock, which has the effect of concentrating voting control with our executive officers and directors; and
|
● |
the limited experience of our management team managing a public company, including a “large accelerated filer.”
|
● |
our sales growth;
|
● |
the costs of applying our existing technologies to new or enhanced products;
|
● |
the costs of developing new technologies and introducing new products;
|
● |
the costs associated with protecting our intellectual property;
|
● |
the costs associated with our expansion, including capital expenditures and Lingang-related land purchases and deposits, and with increasing our sales and marketing and service and support efforts, and with
expanding our geographic operations;
|
● |
our ability to continue to obtain governmental subsidies for developmental projects in the future;
|
● |
future debt repayment obligations; and
|
● |
the number and timing of any future acquisitions.
|
● |
the cyclicality of the semiconductor industry and the related impact on the purchase of equipment used in the manufacture of chips;
|
● |
the timing of purchases of our tools by chip fabricators, which order types of tools based on multi-year capital plans under which the number and dollar amount of tool purchases can vary significantly from
year to year;
|
● |
the relatively high average selling price of our tools and our dependence on a limited number of customers for a substantial portion of our revenue in any period, whereby the timing and volume of purchase
orders or cancellations from our customers could significantly reduce our revenue for that period;
|
● |
the significant expenditures required to customize our products often exceed the deposits received from our customers;
|
● |
the lead time required to manufacture our tools;
|
● |
the timing of recognizing revenue due to the timing of shipment and acceptance of our tools;
|
● |
our ability to sell additional tools to existing customers;
|
● |
the changes in customer specifications or requirements;
|
● |
the length of our product sales cycle;
|
● |
changes in our product mix, including the mix of systems, upgrades, spare parts and service;
|
● |
the timing of our product releases or upgrades or announcements of product releases or upgrades by us or our competitors, including changes in customer orders in anticipation of new products or product
enhancements;
|
● |
our ability to enhance our tools with new and better functionality that meet customer requirements and changing industry trends;
|
● |
constraints on our suppliers’ capacity;
|
● |
our ability to sell our tools to Chinese customers due to regulatory restrictions, including the addition of our customers to the Entity List;
|
● |
the ability of other suppliers to provide sufficient quantities of their tools to our Chinese customers which may indirectly the production plans of our customers and result in a reduction of demand for our
tools;
|
● |
the timing of investments in research and development related to releasing new applications of our technologies and new products;
|
● |
delays in the development and manufacture of our new products and upgraded versions of our products and the market acceptance of these products when introduced;
|
● |
our ability to control costs, including operating expenses and the costs of the components and subassemblies used in our products;
|
● |
the costs related to the acquisition and integration of product lines, technologies or businesses; and
|
● |
the costs associated with protecting our intellectual property, including defending our intellectual property against third-party claims or litigation.
|
● |
our ability to demonstrate the differentiated, innovative nature of our SAPS, TEBO, Tahoe, ECP, furnace and other technologies and the advantages of our tools over those of our competitors;
|
● |
compatibility of our tools with existing or potential customers’ manufacturing processes and products;
|
● |
the level of customer service available to support our products; and
|
● |
the experiences our customers have with our products.
|
● |
accurate anticipation of market requirements, changes in technology and evolving standards;
|
● |
the availability of qualified product designers and technologies needed to solve difficult design challenges in a cost-effective, reliable manner;
|
● |
our ability to design products that meet chip manufacturers’ cost, size, acceptance and specification criteria, and performance requirements;
|
● |
the ability and availability of suppliers and third-party manufacturers to manufacture and deliver the critical components and subassemblies of our tools in a timely manner;
|
● |
market acceptance of our customers’ products, and the lifecycle of those products; and
|
● |
our ability to deliver products in a timely manner within our customers’ product planning and deployment cycle.
|
● |
greater financial, technical, sales and marketing, manufacturing, distribution and other resources;
|
● |
established credibility and market reputations;
|
● |
longer operating histories;
|
● |
broader product offerings;
|
● |
more extensive service offerings, including the ability to have large inventories of spare parts available near, or even at, customer locations;
|
● |
local sales forces; and
|
● |
more extensive geographic coverage.
|
● |
efforts by our sales force;
|
● |
the complexity of our customers’ manufacturing processes and the compatibility of our tools with those processes;
|
● |
our customers’ internal technical capabilities and sophistication; and
|
● |
our customers’ capital spending plans and processes, including budgetary constraints, internal approvals, extended negotiations or administrative delays.
|
● |
our customers may delay or reject acceptance of our tools that contain defects or fail to meet their specifications;
|
● |
we may suffer customer dissatisfaction, negative publicity and reputational damage, resulting in reduced orders or otherwise damaging our ability to retain existing customers and attract new customers;
|
● |
we may incur substantial costs as a result of warranty claims or service obligations or in order to enhance the reliability of our tools;
|
● |
the attention of our technical and management resources may be diverted;
|
● |
we may be required to replace defective systems or invest significant capital to resolve these problems; and
|
● |
we may be required to write off inventory and other assets related to our tools.
|
● |
potential price increases;
|
● |
capacity shortages or other inability to meet any increase in demand for our products;
|
● |
reduced control over manufacturing process for components and subassemblies and delivery schedules;
|
● |
limited ability of some suppliers to manufacture and sell subassemblies or parts in the volumes we require and at acceptable quality levels and prices, due to the suppliers’ relatively small operations and
limited manufacturing resources;
|
● |
increased exposure to potential misappropriation of our intellectual property; and
|
● |
limited warranties on subassemblies and components supplied to us.
|
● |
hire, train, integrate and manage additional qualified engineers for research and development activities, sales and marketing personnel, service and support personnel and financial and information technology
personnel;
|
● |
manage multiple relationships with our customers, suppliers and other third parties; and
|
● |
continue to enhance our information technology infrastructure, systems and controls.
|
● |
the acquired product lines, technologies or businesses may not improve our financial and strategic position as planned;
|
● |
we may determine we have overpaid for the product lines, technologies or businesses, or that the economic conditions underlying our acquisition have changed;
|
● |
we may have difficulty integrating the operations and personnel of the acquired company;
|
● |
we may have difficulty retaining the employees with the technical skills needed to enhance and provide services with respect to the acquired product lines or technologies;
|
● |
the acquisition may be viewed negatively by customers, employees, suppliers, financial markets or investors;
|
● |
we may have difficulty incorporating the acquired product lines or technologies with our existing technologies;
|
● |
we may encounter a competitive response, including price competition or intellectual property litigation;
|
● |
we may encounter difficulties related to required CFIUS approval (see also “—Regulatory and Litigation Risks—Certain of our investments may be subject to review by and approval from CFIUS, which may prevent
us from taking advantage of investment opportunities that would otherwise be advantageous to our stockholders”);
|
● |
we may become a party to product liability or intellectual property infringement claims as a result of our sale of the acquired company’s products;
|
● |
we may incur one-time write-offs, such as acquired in-process research and development costs, and restructuring charges;
|
● |
we may acquire goodwill and other intangible assets that are subject to impairment tests, which could result in future impairment charges;
|
● |
our ongoing business and management’s attention may be disrupted or diverted by transition or integration issues and the complexity of managing geographically or culturally diverse enterprises; and
|
● |
our due diligence process may fail to identify significant existing issues with the target business.
|
● |
a decline in demand for our products;
|
● |
an increase in reserves on accounts receivable due to our customers’ inability to pay us;
|
● |
an increase in reserves on inventory balances due to excess or obsolete inventory as a result of our inability to sell such inventory;
|
● |
valuation allowances on deferred tax assets;
|
● |
restructuring charges;
|
● |
asset impairments including the potential impairment of goodwill and other intangible assets;
|
● |
a decline in the value of our investments;
|
● |
exposure to claims from our suppliers for payment on inventory that is ordered in anticipation of customer purchases that do not come to fruition;
|
● |
a decline in the value of certain facilities we lease to less than our residual value guarantee with the lessor; and
|
● |
challenges maintaining reliable and uninterrupted sources of supply.
|
● |
imposition of, or adverse changes in, foreign laws or regulatory requirements, such as work stoppages and travel restrictions imposed in connection with the COVID-19 pandemic;
|
● |
the need to comply with the import laws and regulations of various foreign jurisdictions, including a range of U.S. import laws;
|
● |
potentially adverse tax consequences, including withholding tax rules that may limit the repatriation of our earnings, and higher effective income tax rates in foreign countries where we conduct business;
|
● |
competition from local suppliers with which potential customers may prefer to do business;
|
● |
seasonal reduction in business activity, such as during the Lunar New Year in parts of Asia and in other periods in various individual countries;
|
● |
increased exposure to foreign currency exchange rates;
|
● |
reduced protection for intellectual property;
|
● |
longer sales cycles and reliance on indirect sales in certain regions;
|
● |
increased length of time for shipping and acceptance of our products;
|
● |
greater difficulty in responding to customer requests for maintenance and spare parts on a timely basis;
|
● |
greater difficulty in enforcing contracts and accounts receivable collection and longer collection periods;
|
● |
difficulties in staffing and managing foreign operations and the increased travel, infrastructure and legal and compliance costs associated with multiple international locations;
|
● |
heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or
irregularities in, our consolidated financial statements; and
|
● |
general economic conditions, geopolitical events or natural disasters in countries where we conduct our operations or where our customers are located, including political unrest, war, acts of terrorism or
responses to such events.
|
• |
In December 2018 the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by U.S. regulators in their oversight of financial statement audits of U.S.-listed reporting companies
with significant operations in the PRC.
|
• |
In June 2019 a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress that, if passed, would have required the SEC to maintain a list of foreign reporting companies for which the
PCAOB is not able to inspect or investigate an auditor report issued by a foreign public accounting firm. The proposed Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges Act, also referred to as the
EQUITABLE Act, would have prescribed increased disclosure requirements for these reporting companies and, beginning in 2025, provided for the delisting from U.S. stock exchanges of reporting companies included on the SEC’s list for three
consecutive years.
|
• |
In May 2020 Nasdaq requested approval by the SEC of proposals that would impact companies with businesses principally administered in jurisdictions defined as “restrictive markets,” which likely would
encompass the PRC. These proposals contemplate, among other things, the application of more stringent listing criteria if a listed company’s auditor does not demonstrate a PCAOB inspection record (as is the case with our auditor), employee
expertise and training, or geographic or other resources sufficient to perform the company’s audit satisfactorily. Examples of more stringent criteria that Nasdaq could apply include requiring: (a) higher levels of equity, assets, earnings
or liquidity than are otherwise needed; (b) that any public offering to be underwritten on a firm commitment basis (involving more due diligence by the underwriter); and (c) the imposition of lock-up restrictions on directors and officers
to allow market mechanisms to determine an appropriate price for shares before the insiders could sell. Alternatively, Nasdaq could deny continued listing to a company.
|
• |
In April 2020 the SEC and the PCAOB issued a joint statement highlighting the significant disclosure, financial reporting and other risks associated with emerging market investments, including the PCAOB’s
continued inability to inspect audit work papers of auditors in the PRC.
|
• |
The Holding Foreign Companies Accountable Act, which became law in December 2020, includes requirements for the SEC to identify
issuers whose audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely because of a restriction imposed by a non-U.S. authority in the auditor’s local jurisdiction. The Holding Foreign Companies
Accountable Act also requires that, to the extent that the PCAOB has been unable to inspect an issuer’s auditor for three consecutive years since 2021, the SEC shall prohibit its securities registered in the United States from being
traded on any national securities exchange or over-the-counter market in the United States. Furthermore, on June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would amend
the Holding Foreign Companies Accountable Act to require the SEC to prohibit an issuer’s securities from trading on any national securities exchange or over-the-counter market in the United States if the PCAOB has been unable to inspect
an issuer’s auditor for two consecutive years instead of three. On September 22, 2021, the PCAOB adopted a final rule implementing the Holding Foreign Companies Accountable Act, which provides a framework for the PCAOB to use when
determining, as contemplated under the Holding Foreign Companies Accountable Act, whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position
taken by one or more authorities in that jurisdiction. On December 16, 2021, the PCAOB designated China and Hong Kong as jurisdictions where the PCAOB is not allowed to conduct full and complete audit inspections and has identified firms
registered in such jurisdictions, including BDO China Shu Lun Pan Certified Public Accountants LLP, our independent registered public accounting firm. Pursuant to each annual determination by the PCAOB, the SEC will, on an annual basis,
identify issuers that have used non-inspected audit firms.
|
● |
The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process.
There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be
able to enter the market earlier than would otherwise have been the case.
|
● |
Patent applications may not result in any patents being issued.
|
● |
Patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage.
|
● |
Our competitors may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use and sell our potential product candidates.
|
● |
The PRC and other countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop
and market competing product candidates.
|
● |
be time consuming and expensive to defend, whether or not meritorious;
|
● |
force us to stop selling products or using technology that allegedly infringes the third party’s intellectual property rights;
|
● |
delay shipments of our products;
|
● |
require us to pay damages or settlement fees to the party claiming infringement;
|
● |
require us to attempt to obtain a license to the relevant intellectual property, which may not be available on reasonable terms or at all;
|
● |
force us to attempt to redesign products that contain the allegedly infringing technology, which could be expensive or which we may be unable to do;
|
● |
require us to indemnify our customers, suppliers or other third parties for any loss caused by their use of our technology that allegedly infringes the third party’s intellectual property rights; or
|
● |
divert the attention of our technical and managerial resources.
|
● |
actual or anticipated fluctuations in our revenue and other operating results;
|
● |
the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;
|
● |
actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet these estimates or the
expectations of investors;
|
● |
changes in projections for the chips or chip equipment industries or in the operating performance or expectations and stock market valuations of chip companies, chip equipment companies or technology
companies in general;
|
● |
changes in operating results;
|
● |
any changes in the financial projections we may provide to the public, our failure to meet these projections, or changes in recommendations by any securities analysts that elect to follow Class A common
stock;
|
● |
additional shares of Class A common stock being sold into the market by us or our existing stockholders or the anticipation of such sales;
|
● |
price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;
|
● |
lawsuits threatened or filed against us;
|
● |
litigation and other developments relating to our patents or other proprietary rights or those of our competitors;
|
● |
developments in new legislation and pending lawsuits or regulatory actions, including interim or final rulings by judicial or regulatory bodies; and
|
● |
general economic trends, including changes in the demand for electronics or information technology or geopolitical events such as war or acts of terrorism, or any responses to such events.
|
● |
our dual class common stock structure provides holders of Class B common stock with the ability to control the outcome of matters requiring stockholder approval, even if they own significantly less than a
majority of the total number of outstanding shares of Class A and Class B common stock;
|
● |
when the outstanding shares of Class B common stock represent less than a majority of the combined voting power of common stock;
|
● |
amendments to our charter or bylaws will require the approval of two-thirds of the combined vote of our then-outstanding shares of Class A and Class B common stock;
|
● |
vacancies on the board of directors will be able to be filled only by the board and not by stockholders;
|
● |
the board, which currently is not staggered, will be automatically separated into three classes with staggered three-year terms;
|
● |
directors will only be able to be removed from office for cause; and
|
● |
our stockholders will only be able to take action at a meeting and not by written consent;
|
● |
only our chair, our chief executive officer or a majority of our directors is authorized to call a special meeting of stockholders;
|
● |
advance notice procedures apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders;
|
● |
our charter authorizes undesignated preferred stock, the terms of which may be established, and shares of which may be issued, without stockholder approval; and
|
● |
cumulative voting in the election of directors is prohibited.
|
● |
any derivative action or proceeding brought on our behalf;
|
● |
any action asserting a claim of breach of a fiduciary duty owed to us, our stockholders, creditors or other constituents by any of our directors, officers, other employees, agents or stockholders;
|
● |
any action asserting a claim arising under the Delaware General Corporation Law, our charter or bylaws, or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the
State of Delaware; or
|
● |
any action asserting a claim that is governed by the internal affairs doctrine.
|
● |
the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002;
|
● |
compliance with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the
financial statements;
|
● |
the requirement that we provide full and more detailed disclosures regarding executive compensation; and
|
● |
the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved.
|
Item 2. |
Properties
|
Item 3. |
Legal Proceedings
|
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
Base
Period
|
Years Ending
|
|||||||||||||||||||||||
Company Name/Index
|
11/3/17
|
12/29/17
|
12/31/18
|
12/31/19
|
12/31/20
|
12/31/21
|
||||||||||||||||||
ACM Research, Inc.
|
$
|
100
|
$
|
87
|
$
|
180
|
$
|
305
|
$
|
1,343
|
$
|
1,409
|
||||||||||||
Russell 1000 Index
|
$
|
100
|
$
|
103
|
$
|
97
|
$
|
124
|
$
|
148
|
$
|
157
|
||||||||||||
Nasdaq Composite Index
|
$
|
100
|
$
|
102
|
$
|
98
|
$
|
133
|
$
|
191
|
$
|
231
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
● |
Space Alternated Phase Shift, or SAPS, technology for flat and patterned wafer surfaces, which employs alternating phases of megasonic waves to deliver megasonic
energy in a highly uniform manner on a microscopic level;
|
● |
Timely Energized Bubble Oscillation, or TEBO, technology for patterned wafer surfaces at advanced process nodes, which provides effective, damage-free cleaning for 2D
and 3D patterned wafers with fine feature sizes;
|
● |
Tahoe technology for cost and environmental savings, which delivers high cleaning performance using significantly less sulfuric acid and hydrogen peroxide than is
typically consumed by conventional high-temperature single-wafer cleaning tools; and
|
● |
Electro-Chemical Plating, or ECP, technology for advanced metal plating, which includes Ultra ECP ap, or Advanced Packaging, technology for back-end assembly
processes, Ultra ECP 3d for through-silicon-via, or tsv, and Ultra ECP map, or Multi-Anode Partial Plating, technology for front-end wafer fabrication processes.
|
• |
a listing, which we refer to as the STAR Listing, of shares of ACM Shanghai on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd, known as the STAR Market; and
|
• |
a concurrent initial public offering, which we refer to as the STAR IPO, of ACM Shanghai shares in the PRC, at a pre-offering valuation of not less than RMB 5.15 billion ($747.1 million).
|
• |
the land lease for, and construction of, ACM Shanghai’s proposed development and production center in the Lingang region of Shanghai;
|
• |
product development to upgrade and expand our process equipment targeted at more advanced process nodes, including technical improvement and development of TEBO megasonic cleaning equipment, Tahoe single
wafer wet bench combined cleaning equipment, front-end brush scrubbing equipment, auto bench and backside cleaning equipment, electroplating equipment, stress free polish equipment, vertical furnace equipment, and additional new products to
expand our product portfolio; and
|
• |
working capital.
|
• |
Operations: We conduct substantially all of our product development, manufacturing, support and services in the PRC, and those activities have been directly impacted
by the COVID–19 pandemic and related restrictions on transportation and public appearances. Currently substantially all of our staff have returned to work at both of our Shanghai facilities. To date we have not experienced absenteeism of
management or other key employees, other than certain of our executive officers being delayed in traveling back to the PRC when working from our California office. Our corporate headquarters are located in Alameda County in the San
Francisco Bay Area and are the subject of a number of state and county public health directives and orders. These actions have not negatively impacted our business to date, however, because of the limited number of employees at our
headquarters and the nature of the work they generally perform.
|
• |
Customers: Our customers’ business operations have been, and are continuing to be, subject to business interruptions arising from the COVID–19 pandemic. Historically a
majority of our revenue has been derived from customers located in the PRC and surrounding areas that have been impacted by COVID–19. Two customers that accounted for 48.9% of our revenue in 2021 are based in the PRC, and three customers
that accounted for 75.8% of our revenue in 2020, and 73.8% of our revenue in 2019 are based in the PRC and South Korea. One of those customers, Yangtze Memory Technologies Co., Ltd. — which accounted for 20.2% of our 2021 revenue, 26.8% of
our 2020 revenue, and 27.5% of our 2019 revenue — is based in Wuhan. While Yangtze Memory Technologies Co., Ltd. and other key customers continued to operate their fabrication facilities without interruption during and after the first
quarter of 2020, have been forced to restrict access of service personnel and deliveries to and from their facilities. We have experienced longer and in some cases more costly shipping expenses in the delivery of tools to certain customers.
|
• |
Suppliers: Our global supply chain includes components sourced from the PRC, Japan, Taiwan, the United States and Europe. While, to date, we have not experienced
material issues with our supply chain, supply chain constraints have intensified due to COVID-19, contributing to global shortages in the supply of semiconductors and other materials used in the production of our own tools. As with our
customers, we continue to be in close contact with our key suppliers to help ensure we are able to identify any potential supply issues that may arise.
|
• |
Projects: Our strategy includes a number of plans to support the growth of our core business, including ACM Shanghai’s acquisition of a land use right in the Lingang
area of Shanghai where we began construction of a new research and development center and factory in July 2020. The extent to which COVID–19 impacts these projects will depend on future developments that are highly uncertain, but to date,
the timing of these ongoing projects has not been delayed or significantly disrupted by COVID–19 or related government measures.
|
● |
Sales and Development. During the sale process we may, depending on a prospective customer’s specifications and requirements, need to perform additional research,
development and testing to establish that a tool can meet the prospective customer’s requirements. We then host an in-house demonstration of the customized tool prototype. Sales cycles for orders that require limited customization and do
not require that we develop new technology usually take from 6 to 12 months, while the product life cycle, including the initial design, demonstration and final assembly phases, for orders requiring development and testing of new
technologies can take as long as 2 to 4 years. As we expand our customer base, we expect to gain more repeat purchase orders for tools that we have already developed and tested, which will reduce the need for a demonstration phase and
shorten the development cycle.
|
● |
Evaluation Periods. When a chip manufacturer proposes to purchase a particular type of tool from us for the first time, we offer the manufacturer an opportunity to
evaluate the tool for a period that can extend for 24 months or longer. In some cases, we do not receive any payment on first-time purchases until the tool is accepted. As a result, we may spend more than $2.0 million to produce a tool
without receiving payment for more than 24 months or, if the tool is not accepted, without receiving any payment. Please see “Item 1A. Risk Factors—Risks Related to Our Business and Our Industry—We may incur significant expenses long before
we can recognize revenue from new products, if at all, due to the costs and length of research, development, manufacturing and customer evaluation process cycles.”
|
● |
Purchase Orders. In accordance with industry practice, sales of our tools are made pursuant to purchase orders. Each purchase order from a customer for one of our
tools contains specific technical requirements intended to ensure, among other things, that the tool will be compatible with the customer’s manufacturing process line. Until a purchase order is received, we do not have a binding purchase
commitment. Some of our customers to date have provided us with non-binding one- to two-year forecasts of their anticipated demands, and we expect future customers to furnish similar non-binding forecasts for planning purposes. Any of those
forecasts would be subject to change, however, by the customer at any time, without notice to us.
|
● |
Fulfillment. We seek to obtain a purchase order for a tool from three to four months in advance of the expected delivery date. Depending upon the nature of a
customer’s specifications, the lead time for production of a tool generally will extend from two to four months. The lead-time can be more than six months, however, and in some cases we may need to begin producing a tool based on a
customer’s non-binding forecast, rather than waiting to receive a binding purchase order.
|
● |
direct costs, which consist principally of costs of tool components and subassemblies purchased from third-party vendors;
|
● |
compensation of personnel associated with our manufacturing operations, including stock-based compensation;
|
● |
depreciation of manufacturing equipment;
|
● |
amortization of costs of software used for manufacturing purposes;
|
● |
other expenses attributable to our manufacturing department; and
|
● |
allocated overhead for rent and utilities.
|
● |
compensation of personnel associated with pre- and after-sales support and other sales and marketing activities, including stock-based compensation;
|
● |
sales commissions paid to independent sales representatives;
|
● |
fees paid to sales consultants;
|
● |
cost of trade shows;
|
● |
travel and entertainment; and
|
● |
allocated overhead for rent and utilities.
|
● |
compensation of personnel associated with our research and development activities, including stock-based compensation;
|
● |
costs of components and other research and development supplies;
|
● |
travel expense associated with customer support;
|
● |
amortization of costs of software used for research and development purposes; and
|
● |
allocated overhead for rent and utilities.
|
● |
compensation of executive, accounting and finance, human resources, information technology, and other administrative personnel, including stock-based compensation;
|
● |
professional fees, including accounting and legal fees;
|
● |
other corporate expenses; and
|
● |
allocated overhead for rent and utilities.
|
● |
Stock-based awards granted to employees and non-employees are measured at the fair value of the awards on the grant date and are recognized as expenses either (a) immediately on grant, if no vesting
conditions are required, or (b) using the graded vesting method, net of estimated forfeitures, over the requisite service period. The fair value of stock options is determined using the Black-Scholes valuation model. Stock-based
compensation expense, when recognized, is charged to cost of revenue or to the category of operating expense corresponding to the service function of the employee or non-employee.
|
● |
We also grant discounts to employees when they subscribe for the new shares of ACM Shanghai, and we account for those stock-based awards in accordance with Accounting Standards Codification, or ASC, Topic
718, Compensation—Stock Compensation
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Stock-Based Compensation Expense:
|
||||||||||||
Cost of revenue
|
$
|
397
|
$
|
175
|
$
|
250
|
||||||
Sales and marketing expense
|
1,802
|
1,199
|
328
|
|||||||||
Research and development expense
|
1,115
|
763
|
1,093
|
|||||||||
General and administrative expense
|
1,803
|
3,491
|
1,901
|
|||||||||
$
|
5,117
|
$
|
5,628
|
$
|
3,572
|
● |
Government subsidies relating to current expenses are recorded as reductions of those expenses in the periods in which the current expenses are recorded. For the years ended December 31, 2021, 2020 and 2019,
related government subsidies recognized as reductions of relevant expenses in the consolidated statements of operations and comprehensive income were $11.3 million, $2.7 million , and $3.2 million, respectively.
|
● |
Government subsidies related to depreciable assets are credited to income over the useful lives of the related assets for which the grant was received. For the years ended December 31, 2021, 2020 and 2019,
related government subsidies recognized as other income in the consolidated statements of operations and comprehensive income were $200,000, $149,000, and $147,000, respectively.
|
● |
We define “shipments” of tools to include (a) a “repeat” delivery to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue upon delivery, and (b) a
“first-time” delivery of a “first tool” to a customer on an approval basis, for which we may recognize revenue in the future if contractual conditions are met, or if a purchase order is received.
|
● |
We define “adjusted EBITDA” as our net income excluding interest expense (net), income tax benefit (expense), depreciation and amortization, and stock-based compensation. We define adjusted EBITDA to also
exclude restructuring costs, although we have not incurred any such costs to date.
|
● |
We define “free cash flow” as net cash provided by operating activities less purchases of property and equipment (net of proceeds from disposals) and of intangible assets.
|
● |
We define “adjusted operating income (loss)” as our income (loss) from operations excluding stock-based compensation.
|
● |
a shipment to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue when the tool is delivered; and
|
● |
a shipment to a customer of a type of tool that the customer is receiving and evaluating for the first time, in each case a “first tool,” for which we may recognize revenue at a later date, subject to the
customer’s acceptance of the tool upon the tool’s satisfaction of applicable contractual requirements or subject to the costumer’s subsequent discretionary commitment to purchase the tool.
|
● |
adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future;
|
● |
we exclude stock-based compensation expense from adjusted EBITDA and adjusted operating income (loss), although (a) it has been, and will continue to be for the foreseeable future, a significant recurring
expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be
higher, which would affect our cash position;
|
● |
the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report
their operating results;
|
● |
adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
|
● |
adjusted EBITDA does not reflect interest expense, or the requirements necessary to service interest or principal payments on debt;
|
● |
adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;
|
● |
adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
|
● |
although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect any cash
requirements for such replacements; and
|
● |
adjusted EBITDA includes expense reductions and non-operating other income attributable to PRC governmental grants, which may mask the effect of underlying developments in net income, including trends in
current expenses and interest expense, and free cash flow includes the PRC governmental grants, the amount and timing of which can be difficult to predict and are outside our control.
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
(in thousands)
|
||||||||||||
Adjusted EBITDA Data:
|
||||||||||||
Net Income
|
$
|
42,921
|
$
|
21,677
|
$
|
19,458
|
||||||
Interest expense, net
|
260
|
85
|
412
|
|||||||||
Income tax expense (benefit)
|
134
|
(2,382
|
)
|
(518
|
)
|
|||||||
Depreciation and amortization
|
2,353
|
1,055
|
788
|
|||||||||
Stock based compensation
|
5,117
|
5,628
|
3,572
|
|||||||||
Change in fair value of financial liability
|
-
|
11,964
|
-
|
|||||||||
Unrealized gain on trading securities
|
(607
|
)
|
(12,574
|
)
|
-
|
|||||||
Adjusted EBITDA
|
$
|
50,178
|
$
|
25,453
|
$
|
23,712
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
(in thousands)
|
||||||||||||
Free Cash Flow Data:
|
||||||||||||
Net cash used in (provided by) in operating activities
|
$
|
(40,093
|
)
|
$
|
(13,547
|
)
|
$
|
9,403
|
||||
Purchase property and equipment
|
(9,153
|
)
|
(5,211
|
)
|
(971
|
)
|
||||||
Purchase of intangible assets
|
(559
|
)
|
(324
|
)
|
(154
|
)
|
||||||
Purchase of land-use-right
|
-
|
(9,744
|
)
|
-
|
||||||||
Prepayment for property
|
-
|
(40,206
|
)
|
-
|
||||||||
Purchase of trading securities
|
-
|
(15,020
|
)
|
-
|
||||||||
Free cash flow
|
$
|
(49,805
|
)
|
$
|
(84,052
|
)
|
$
|
8,278
|
`
|
Year Ended December 31,
|
|||||||||||||||||||||||||||||||||||
2021
|
2020
|
2019
|
||||||||||||||||||||||||||||||||||
Actual
(GAAP)
|
SBC
|
Adjusted
(Non-
GAAP)
|
Actual
(GAAP)
|
SBC
|
Adjusted
(Non-GAAP)
|
Actual
(GAAP)
|
SBC
|
Adjusted
(Non-GAAP)
|
||||||||||||||||||||||||||||
(in thousands)
|
||||||||||||||||||||||||||||||||||||
Revenue
|
$
|
259,751
|
$
|
-
|
$
|
259,751
|
$
|
156,624
|
$
|
-
|
$
|
156,624
|
$
|
107,524
|
$
|
-
|
$
|
107,524
|
||||||||||||||||||
Cost of revenue
|
(144,895
|
)
|
(397
|
)
|
(144,498
|
)
|
(87,025
|
)
|
(175
|
)
|
(86,850
|
)
|
(56,870
|
)
|
(250
|
)
|
(56,620
|
)
|
||||||||||||||||||
Gross profit
|
114,856
|
(397
|
)
|
115,253
|
69,599
|
(175
|
)
|
69,774
|
50,654
|
(250
|
)
|
50,904
|
||||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||||||
Sales and marketing
|
(26,733
|
)
|
(1,802
|
)
|
(24,931
|
)
|
(16,773
|
)
|
(1,199
|
)
|
(15,574
|
)
|
(11,902
|
)
|
(328
|
)
|
(11,574
|
)
|
||||||||||||||||||
Research and development
|
(34,207
|
)
|
(1,115
|
)
|
(33,092
|
)
|
(19,119
|
)
|
(763
|
)
|
(18,356
|
)
|
(12,900
|
)
|
(1,093
|
)
|
(11,807
|
)
|
||||||||||||||||||
General and administrative
|
(15,214
|
)
|
(1,803
|
)
|
(13,411
|
)
|
(12,215
|
)
|
(3,491
|
)
|
(8,724
|
)
|
(8,061
|
)
|
(1,901
|
)
|
(6,160
|
)
|
||||||||||||||||||
Income (loss) from operations
|
38,702
|
(5,117
|
)
|
43,819
|
21,492
|
(5,628
|
)
|
27,120
|
17,791
|
(3,572
|
)
|
21,363
|
1. |
identify the contract(s) with a customer;
|
2. |
identify the performance obligations in the contract;
|
3. |
determine the transaction price;
|
4. |
allocate the transaction price to the performance obligations in the contract; and
|
5. |
recognize revenue when (or as) the entity satisfies a performance obligation.
|
● |
when the customer has previously accepted the same tool with the same specifications and we can objectively demonstrate that the tool meets all of the required acceptance criteria;
|
● |
when the sales contract or purchase order contains no acceptance agreement or lapsing acceptance provision and we can objectively demonstrate that the tool meets all of the required acceptance criteria;
|
● |
when the customer withholds acceptance due to issues unrelated to product performance, in which case revenue is recognized when the system is performing as intended and meets predetermined specifications; or
|
● |
when our sales arrangements do not include a general right of return.
|
● |
We use the market closing price for the Class A common stock as reported on the Nasdaq Global Market to determine the fair value of the Class A common stock.
|
● |
The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. Treasury securities.
|
● |
Due to a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly
traded. For these analyses, we have selected companies with comparable characteristics to ours including enterprise value, risk profile, position within the industry, and with historical share price information sufficient to meet the
expected life of the stock-based awards. We compute the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of our stock-based awards. We
will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.
|
● |
The expected term represents the period of time that options are expected to be outstanding. The expected term of stock options is based on the average between the vesting period and the contractual term for
each grant according to Staff Accounting Bulletin No. 110.
|
● |
The expected dividend yield is assumed to be 0%, based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends.
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Revenue
|
100.0
|
%
|
100.0
|
%
|
100.0
|
%
|
||||||
Cost of revenue
|
55.8
|
55.6
|
52.9
|
|||||||||
Gross margin
|
44.2
|
44.4
|
47.1
|
|||||||||
Operating expenses:
|
||||||||||||
Sales and marketing
|
10.3
|
10.7
|
11.1
|
|||||||||
Research and development
|
13.2
|
12.2
|
12.0
|
|||||||||
General and administrative
|
5.9
|
7.8
|
7.5
|
|||||||||
Total operating expenses, net
|
29.4
|
30.7
|
30.6
|
|||||||||
Income from operations
|
14.8
|
13.7
|
16.5
|
|||||||||
Interest income (expense), net
|
(0.1
|
)
|
(0.1
|
)
|
(0.4
|
)
|
||||||
Change in fair value of financial liability
|
-
|
(7.6
|
)
|
-
|
||||||||
Unrealized gain on trading securities
|
0.2
|
8.0
|
-
|
|||||||||
Other income (expense), net
|
(0.2
|
)
|
(2.2
|
)
|
1.3
|
|||||||
Equity income in net income of affiliates
|
1.8
|
0.4
|
0.2
|
|||||||||
Income before income taxes
|
16.5
|
12.3
|
17.6
|
|||||||||
Income tax benefit (expense)
|
(0.1
|
)
|
1.5
|
0.5
|
||||||||
Net income
|
16.4
|
13.8
|
18.1
|
|||||||||
Less: Net income attributable to non-controlling interests and redeemable non-controlling interests
|
2.0
|
1.8
|
0.4
|
|||||||||
Net income attributable to ACM Research, Inc.
|
14.4
|
%
|
12.0
|
%
|
17.7
|
%
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Single Wafer Cleaning, Tahoe and Semi-Critical Cleaning Equipment
|
$
|
189,208
|
$
|
131,248
|
90,501
|
|||||||
ECP (front-end and packaging), Furnace and Other Technologies
|
33,210
|
13,343
|
6,900
|
|||||||||
Advanced Packaging (excluding ECP), Services & Spares
|
37,333
|
12,033
|
10,124
|
|||||||||
Total Revenue By Product Category
|
$
|
259,751
|
$
|
156,624
|
107,524
|
|||||||
Wet cleaning and other front-end processing tools
|
$
|
202,268
|
$
|
136,317
|
90,935
|
|||||||
Advanced packaging, other processing tools, services and spares
|
57,483
|
20,307
|
16,590
|
|||||||||
Total Revenue Front-end and Back-End
|
$
|
259,751
|
$
|
156,624
|
107,524
|
|||||||
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Mainland China
|
$
|
258,615
|
$
|
154,359
|
103,467
|
|||||||
Other Regions
|
1,136
|
2,265
|
4,057
|
|||||||||
$
|
259,751
|
$
|
156,624
|
107,524
|
Year Ended December 31,
|
||||||||||||||||||||
2021
|
2020
|
2019
|
% Change
2021 v 2020
|
% Change
2020 v 2019
|
||||||||||||||||
(in thousands)
|
||||||||||||||||||||
Cost of revenue
|
$
|
144,895
|
$
|
87,025
|
$
|
56,870
|
66.5
|
%
|
53.0
|
%
|
||||||||||
Gross profit
|
114,856
|
69,599
|
50,654
|
65.0
|
%
|
37.4
|
%
|
|||||||||||||
Gross margin
|
44.2
|
%
|
44.4
|
%
|
47.1
|
%
|
-0.2
|
-2.67
|
Year Ended December 31,
|
||||||||||||||||||||
2021
|
2020
|
2019
|
% Change
2021 v 2020
|
% Change
2020 v 2019
|
||||||||||||||||
(in thousands)
|
||||||||||||||||||||
Sales and marketing expense
|
$
|
26,733
|
$
|
16,773
|
$
|
11,902
|
59.4
|
%
|
40.9
|
%
|
||||||||||
Research and development expense
|
34,207
|
19,119
|
12,900
|
78.9
|
%
|
48.2
|
%
|
|||||||||||||
General and administrative expense
|
15,214
|
12,215
|
8,061
|
24.6
|
%
|
51.5
|
%
|
|||||||||||||
Total operating expenses
|
$
|
76,154
|
$
|
48,107
|
$
|
32,863
|
58.3
|
%
|
46.4
|
%
|
Year Ended December 31,
|
|||||||||||||||||
2021
|
2020
|
2019
|
% Change
2021 v 2020
|
% Change
2020 v 2019
|
|||||||||||||
(in thousands)
|
|||||||||||||||||
Unrealized gain on trading securities
|
607
|
12,574
|
-
|
-95.2
|
%
|
NM
|
|||||||||||
Change in fair value of financial liability and trading securities
|
-
|
(11,964
|
)
|
-
|
NM
|
NM
|
Year Ended December 31,
|
||||||||||||||||||||
2021
|
2020
|
2019
|
% Change
2021 v 2020
|
% Change
2020 v 2019
|
||||||||||||||||
(in thousands)
|
||||||||||||||||||||
Interest Income
|
$
|
505
|
$
|
897
|
$
|
333
|
-43.7
|
%
|
169.4
|
%
|
||||||||||
Interest Expense
|
(765
|
)
|
(982
|
)
|
(745
|
)
|
-22.1
|
%
|
31.8
|
%
|
||||||||||
Interest Income (expense), net
|
$
|
(260
|
)
|
$
|
(85
|
)
|
$
|
(412
|
)
|
205.9
|
%
|
-79.4
|
%
|
|||||||
Other income (expense), net
|
$
|
(631
|
)
|
$
|
(3,377
|
)
|
$
|
1,393
|
-81.3
|
%
|
-342.4
|
%
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
(in thousands)
|
||||||||||||
Current:
|
||||||||||||
U.S. federal
|
$
|
(91
|
)
|
$
|
(61
|
)
|
- | |||||
U.S. state
|
(2
|
)
|
(2
|
)
|
- | |||||||
Foreign
|
(2,195
|
)
|
(2,014
|
)
|
(3,176
|
)
|
||||||
Total current tax expense
|
(2,288
|
)
|
(2,077
|
)
|
(3,176
|
)
|
||||||
Deferred:
|
||||||||||||
U.S. federal
|
2,089
|
7,325
|
3,728
|
|||||||||
U.S. state
|
-
|
-
|
- |
|||||||||
Foreign
|
65
|
(2,866
|
)
|
(34
|
)
|
|||||||
Total deferred tax benefit
|
2,154
|
4,459
|
3,694
|
|||||||||
Total income tax benefit (expense)
|
$
|
(134
|
)
|
$
|
2,382
|
$
|
518
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
(in thousands)
|
||||||||||||
Net income attributable to non-controlling interests and redeemable non-controlling interests
|
$
|
5,607
|
$
|
6,858
|
$
|
483
|
• |
the start of construction within 6 months after the Delivery Date (60% of the performance deposit);
|
• |
the completion of construction within 30 months after the Delivery Date (20% of the performance deposit); and
|
• |
the start of production within 42 months after the Delivery Date (20% of the performance deposit).
|
Lender
|
Agreement Date
|
Maturity Date
|
Annual
Interest Rate
|
Maximum
Borrowing
Amount(1)
|
Amount
Outstanding
at December 31,
2021
|
|||||||||||
(in thousands)
|
||||||||||||||||
Bank of Shanghai Pudong Branch
|
June 2021
|
June 2022
|
2.70
|
%
|
RMB100,000
|
RMB29,439
|
||||||||||
$
|
15,680
|
$
|
4,616
|
|||||||||||||
China Everbright Bank
|
July 2021
|
October 2022
|
1.95
|
%
|
RMB150,000
|
RMB21,731
|
||||||||||
$
|
23,520
|
$
|
3,407
|
|||||||||||||
Bank of Communications
|
October 2021
|
October 2022
|
3.85
|
%
|
RMB60,000
|
RMB10,000
|
||||||||||
$
|
9,408
|
$
|
1,568
|
|||||||||||||
China Merchants Bank
|
November 2020
|
Repayable by installments and the last installments repayble in November 2030
|
4.65
|
%
|
RMB128,500
|
RMB117,281
|
||||||||||
$
|
20,149
|
$
|
18,390
|
|||||||||||||
Bank of China
|
June 2021
|
Repayable by installments and the last installments repayble in June 2024
|
2.60
|
%
|
RMB10,000
|
RMB9,500
|
||||||||||
$
|
1,568
|
$
|
1,490
|
|||||||||||||
Bank of China
|
September, 2021
|
Repayable by installments and the last installments repayble in September 2021
|
2.60
|
%
|
RMB35,000
|
RMB35,000
|
||||||||||
$
|
5,487
|
$
|
5,487
|
|||||||||||||
$
|
75,812
|
$
|
34,958
|
(1) |
Converted from RMB to dollars as of December 31, 2021. All of the amounts owing under the line of credit of Bank of Shanghai, Pudong Branch is guaranteed by CleanChip Technologies LTD,
a wholly owned subsidiary of ACM Shanghai.
|
December 31, 2021
|
||||
(in thousands)
|
||||
Cash and cash equivalents
|
$
|
563,067
|
||
Accounts receivable, less allowance for doubtful amounts
|
105,553
|
|||
Inventory
|
218,116
|
|||
Working capital
|
$
|
886,736
|
Item 7A. |
Quantitative and Qualitative Disclosures About Market Risk
|
Item 8. |
Financial Statements and Supplementary Data
|
|
Page
|
Consolidated Financial Statements
|
80 |
|
|
Report of Independent Registered Public Accounting Firm (
|
81
|
|
|
Consolidated Balance Sheets as of December 31, 2021
and 2020
|
84
|
|
|
Consolidated Statements of Operations and Comprehensive Income for the Years ended December 31, 2021, 2020 and 2019
|
85
|
|
|
Consolidated Statements of Changes in Stockholders’ Equity for the Years ended December 31, 2021, 2020 and 2019
|
86
|
|
|
Consolidated Statements of Cash Flows for the Years ended December 31, 2021, 2020 and 2019
|
87
|
|
|
Notes to Consolidated Financial Statements
|
88 |
• |
Testing the design and operating effectiveness of controls over revenue recognition including management’s controls related to the identification and
evaluation of performance obligations in contracts with customers and assessment of contract terms.
|
• |
Evaluating management’s accounting policies and practices including the reasonableness of management’s judgments and assumptions relating to the
Company’s revenue recognition including evaluation of customer acceptance clauses.
|
• |
Testing a sample of revenue contracts and underlying order documents to evaluate appropriateness of management’s revenue recognition including
assessment of customer acceptance clauses.
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Trading securities (note 16)
|
|
|
||||||
Accounts receivable, less allowance for doubtful accounts of $
|
|
|
||||||
Income tax recoverable |
||||||||
Other receivables
|
|
|
||||||
Inventories (note 5)
|
|
|
||||||
Prepaid expenses
|
|
|
||||||
Total current assets
|
|
|
||||||
Property, plant and equipment, net (note 6)
|
|
|
||||||
Land use right, net (note 7)
|
|
|
||||||
Operating lease right-of-use assets, net (note 11)
|
|
|
||||||
Intangible assets, net
|
|
|
||||||
Deferred tax assets (note 21)
|
|
|
||||||
Long-term investments (note 14)
|
|
|
||||||
Other long-term assets (note 8)
|
|
|
||||||
Total assets
|
|
|
||||||
Liabilities and Stockholders’ Equity
|
||||||||
Current liabilities:
|
||||||||
Short-term borrowings (note 9)
|
|
|
||||||
Current portion of long-term borrowings (note 12)
|
|
|
||||||
Accounts payable
|
|
|
||||||
Advances from customers
|
|
|
||||||
Deferred revenue
|
|
|
||||||
Income taxes payable (note 21)
|
|
|
||||||
FIN-48 payable (note 21)
|
|
|
||||||
Other payables and accrued expenses (note 10)
|
|
|
||||||
Current portion of operating lease liability (note 11)
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Long-term borrowings (note 12)
|
|
|
||||||
Long-term operating lease liability (note 11)
|
|
|
||||||
Deferred tax liability (note 21)
|
|
|
||||||
Other long-term liabilities (note 13)
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies (note 23)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Common stock – Class A, par value $
|
|
|
||||||
Common stock–Class B, par value $
|
|
|
||||||
Additional paid in capital
|
|
|
||||||
Accumulated surplus
|
|
|
||||||
Accumulated other comprehensive income
|
|
|
||||||
Total ACM Research, Inc. stockholders’ equity
|
|
|
||||||
Non-controlling interests
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Revenue (note 3)
|
$
|
|
$
|
|
$
|
|
||||||
Cost of revenue
|
|
|
|
|||||||||
Gross profit
|
|
|
|
|||||||||
Operating expenses:
|
||||||||||||
Sales and marketing
|
|
|
|
|||||||||
Research and development
|
|
|
|
|||||||||
General and administrative
|
|
|
|
|||||||||
Total operating expenses, net
|
|
|
|
|||||||||
Income from operations
|
|
|
|
|||||||||
Interest income
|
|
|
|
|||||||||
Interest expense
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in fair value of financial liability
|
|
(
|
)
|
|
||||||||
Unrealized gain on trading securities
|
|
|
|
|||||||||
Other income (expense), net
|
(
|
)
|
(
|
)
|
|
|||||||
Equity income in net income of affiliates
|
|
|
|
|||||||||
Income before income taxes
|
|
|
|
|||||||||
Income tax benefit (expense) (note 21)
|
(
|
)
|
|
|
||||||||
Net income
|
|
|
|
|||||||||
Less: Net income attributable to non-controlling interests and redeemable non-controlling interests
|
|
|
|
|||||||||
Net income attributable to ACM Research, Inc.
|
$
|
|
$
|
|
$
|
|
||||||
Comprehensive income:
|
||||||||||||
Net income
|
|
|
|
|||||||||
Foreign currency translation adjustment
|
|
|
(
|
)
|
||||||||
Comprehensive Income
|
|
|
|
|||||||||
Less: Comprehensive income attributable to non-controlling interests and redeemable non-controlling interests
|
|
|
|
|||||||||
Comprehensive income attributable to ACM Research, Inc.
|
$
|
|
$
|
|
$
|
|
||||||
Net income attributable to ACM Research, Inc. per common share (note 2):
|
||||||||||||
Basic
|
$
|
|
$
|
|
$
|
|
||||||
Diluted
|
$
|
|
$
|
|
$
|
|
||||||
Weighted average common shares outstanding used in computing per share amounts (note 2):
|
||||||||||||
Basic
|
|
|
|
|||||||||
Diluted
|
|
|
|
Common
Stock Class A
|
Common
Stock Class B
|
|||||||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Additional Paid-
in Capital
|
Accumulated Surplus
(Deficit)
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Non-controlling
interests
|
Total
Stockholders’
Equity
|
||||||||||||||||||||||||||||
Balance at December 31, 2018
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
||||||||||||||||||
Net income attributable to ACM Research, Inc.
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Foreign currency translation adjustment
|
-
|
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||||||||
Exercise of stock options
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Cancellation of stock options
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
Stock-based compensation
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Issuance of Class A common stock in connection with public offering
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Share repurchase
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||||||||||||
Conversion of Class B common stock to Class A common stock
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Exercise of stock warrants issued to HFG
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Balance at December 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||||
Net income
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Foreign currency translation adjustment
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Exercise of stock options
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Stock-based compensation
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Conversion of class B common shares to Class A common shares
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||||||||||||||||||
Share cancellation (note 16)
|
(
|
)
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||||||||||
Issuance of warrants (note 16)
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Exercise of stock warrants
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||
Reclassification of redeemable non-controlling interest
|
-
|
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Balance at December 31, 2020
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Net income |
- |
- |
||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
- |
- |
||||||||||||||||||||||||||||||||||
Exercise of stock options |
||||||||||||||||||||||||||||||||||||
Stock-based compensation |
- |
- |
||||||||||||||||||||||||||||||||||
Exercise of warrants |
||||||||||||||||||||||||||||||||||||
Conversion of Class B common stock to Class A common stock |
( |
) | ||||||||||||||||||||||||||||||||||
Proceeds from a subsidiary equity issuance, net of issuance costs |
||||||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | $ |
$ |
$ |
$ |
$ |
$ |
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net income
|
$
|
|
$
|
|
$
|
|
||||||
Adjustments to reconcile net income from operations to net cash used in operating activities
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Loss on disposals of property, plant and equipment
|
|
|
|
|||||||||
Equity income in net income of affiliates
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Unrealized gain on trading securities
|
(
|
)
|
(
|
)
|
|
|||||||
Deferred income taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Stock-based compensation
|
|
|
|
|||||||||
Change in fair value of financial liability
|
|
|
|
|||||||||
Net changes in operating assets and liabilities:
|
||||||||||||
Accounts receivable
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Income tax recoverable
|
( |
) | ||||||||||
Other receivables
|
(
|
)
|
(
|
)
|
|
|||||||
Inventory
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Prepaid expenses
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Other long-term assets
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Accounts payable
|
|
|
(
|
)
|
||||||||
Advances from customers
|
|
|
|
|||||||||
Income tax payable
|
|
(
|
)
|
|
||||||||
FIN-48 payable
|
|
(
|
)
|
|
||||||||
Other payables and accrued expenses
|
|
|
|
|||||||||
Deferred revenue
|
|
|
|
|||||||||
Other long-term liabilities
|
|
|
(
|
)
|
||||||||
Net cash flow (used in) provided by operating activities
|
(
|
)
|
(
|
)
|
|
|||||||
Cash flows from investing activities:
|
||||||||||||
Purchase of property and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Purchase of intangible assets
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Purchase of land-use-right
|
|
(
|
)
|
|
||||||||
Purchase of trading securities
|
|
(
|
)
|
|
||||||||
Prepayment for property
|
|
(
|
)
|
|
||||||||
Investments in unconsolidated affiliates
|
(
|
)
|
|
(
|
)
|
|||||||
Dividends from unconsolidated affiliates
|
|
|
|
|||||||||
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from short-term borrowings
|
|
|
|
|||||||||
Repayments of short-term borrowings
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from long-term borrowings
|
|
|
|
|||||||||
Repayments of long-term borrowings
|
(
|
)
|
(
|
)
|
|
|||||||
Repayments of notes payable
|
|
(
|
)
|
|
||||||||
Proceeds from stock option exercise to common stock
|
|
|
|
|||||||||
Proceeds from issuance of Class A common stock in connection with public offering, net of direct issuance expenses of $
|
|
|
|
|||||||||
Payment for repurchase of Class A common stock
|
|
|
(
|
)
|
||||||||
Payment for cancellation of stock option
|
|
|
(
|
)
|
||||||||
Proceeds from issuance of common stock to redeemable Non-controlling interest
|
|
|
|
|||||||||
Proceeds from a subsidiary equity issuance, net of issuance costs |
||||||||||||
Proceeds from warrant exercise to common stock |
||||||||||||
Net cash provided by financing activities
|
|
|
|
|||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||
Net increase (decrease) in cash, cash equivalents and restricted cash
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Cash, cash equivalents and restricted cash at beginning of period
|
|
|
|
|||||||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
|
$
|
|
$
|
|
||||||
Supplemental disclosure of cash flow information:
|
||||||||||||
Interest paid, net of capitalized interest
|
$
|
|
$
|
|
$
|
|
||||||
Cash paid for income taxes
|
$
|
|
$
|
|
$
|
|
||||||
Reconciliation of cash, cash equivalents and restricted cash in condensed consolidated statements of
cash flows:
|
||||||||||||
Cash and cash equivalents
|
|
|
|
|||||||||
Restricted cash
|
|
|
|
|||||||||
Cash, cash equivalents and restricted cash
|
$
|
|
$
|
|
$
|
|
||||||
Non-cash financing activities:
|
||||||||||||
Warrant conversion to common stock
|
$
|
|
$
|
|
$
|
|
||||||
Share cancellation, (note 16)
|
$
|
|
$
|
|
$
|
|
||||||
Cashless exercise of stock options |
$ | $ | $ | |||||||||
Issuance of warrant for settlement of financial liability and cancellation of note receivable
|
$
|
|
$
|
|
$
|
|
Place and date of
|
Effective interest held as at
December 31,
|
||
Name of subsidiaries
|
incorporation
|
2021
|
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NM |
● |
The cost of a general inventory item is determined using the weighted moving average method. Under the weighted moving average method, the Company calculates the new average price
of all items of a particular inventory stock each time one or more items of that stock are purchased. The then-current average price of the stock is used for purposes of determining cost of inventory or cost of revenue. The cost of an
inventory item purchased specifically for a customized product is determined using the specific identification method. Low-cost consumable materials and packaging materials are expensed as incurred.
|
● |
Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete or dispose.
|
Computer and office equipment
|
|
Furniture and fixtures
|
|
Leasehold improvements
|
shorter of lease term or estimated useful life
|
Manufacturing equipment
|
for small to medium-sized equipment,
estimated by purchasing department at time of acceptance
|
Furniture and fixtures
|
|
Transportation equipment
|
|
Electronic equipment
|
|
Leasehold improvements
|
remaining lease term for improvements on leased fixed assets or,
for large improvements, estimated useful life;
not less than
|
1. |
Identify the contract(s) with a customer;
|
2. |
Identify the performance obligations in the contract;
|
3. |
Determine the transaction price;
|
4. |
Allocate the transaction price to the performance obligations in the contract; and
|
5. |
Recognize revenue when (or as) the entity satisfies a performance obligation.
|
● |
When the customer has previously accepted the same tool with the same specifications and the Company can objectively demonstrate that the tool meets all of the required acceptance
criteria;
|
● |
When the sales contract or purchase order contains no acceptance agreement or lapsing acceptance provision and the Company can objectively demonstrate that the tool meets all of
the required acceptance criteria;
|
● |
When the customer withholds acceptance due to issues unrelated to product performance, in which case revenue is recognized when the system is performing as intended and meets
predetermined specifications; or
|
● |
When the Company’s sales arrangements do not include a general right of return.
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Balance at beginning of period
|
|
|
|
|
|
|
||||||
Additions
|
|
|
|
|||||||||
Utilized
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Balance at end of period
|
$
|
|
$
|
|
$
|
|
● |
Government subsidies relating to current expenses are recorded as reductions of those expenses in the periods in which the current expenses are recorded. For the years ended December
31, 2021, 2020 and 2019, related government subsidies recognized as reductions of relevant expenses in the consolidated statements of operations and comprehensive income were $
|
● |
Government subsidies related to depreciable assets are credited to income over the useful lives of the related assets for which the grant was received. For the years ended December
31, 2021, 2020 and 2019, related government subsidies recognized as other income in the consolidated statements of operations and comprehensive income were $
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Numerator:
|
||||||||||||
Net income
|
$
|
|
$
|
|
$
|
|
||||||
Less: Net income attributable to non-controlling interests and redeemable non-controlling interests
|
|
|
|
|||||||||
Net income available to common stockholders, basic |
$ |
$ | $ |
|||||||||
Less: Dilutive effect arising from share-based awards by ACM Shanghai
|
||||||||||||
Net income available to common stockholders, diluted
|
$
|
|
$
|
|
$
|
|
||||||
Weighted average shares outstanding, basic
|
|
|
|
|||||||||
Effect of dilutive securities
|
|
|
|
|||||||||
Weighted average shares outstanding, diluted
|
|
|
|
|||||||||
Net income per common share:
|
||||||||||||
Basic
|
|
|
|
|||||||||
Diluted
|
$
|
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Customer A
|
|
%
|
|
%
|
||||
Customer B
|
|
%
|
|
%
|
||||
Customer C
|
|
|
%
|
|||||
Total
|
|
%
|
|
%
|
At December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Consolidated balance sheets:
|
||||||||||||
RMB to $1.00
|
|
|
|
|||||||||
KRW to $1.00
|
|
|
|
Consolidated statements of operations and comprehensive income:
|
||||||||||||
RMB to $1.00
|
|
|
|
|||||||||
KRW to $1.00
|
|
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Single Wafer Cleaning, Tahoe and Semi-Critical Cleaning Equipment
|
$
|
|
$
|
|
|
|
||||||
ECP (front-end and packaging), Furnace and Other Technologies
|
|
|
|
|||||||||
Advanced Packaging (excluding ECP), Services & Spares
|
|
|
|
|||||||||
Total Revenue By Product Category
|
$
|
|
$
|
|
|
|
||||||
Wet cleaning and other front-end processing tools
|
$ |
|
$ |
|
|
|||||||
Advanced packaging, other processing tools, services and spares
|
|
|
|
|||||||||
Total Revenue Front-end and Back-End
|
$
|
|
$
|
|
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Mainland China
|
$
|
|
$
|
|
|
|
||||||
Other Regions
|
|
|
|
|||||||||
$
|
|
$
|
|
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Accounts receivable
|
$
|
|
$
|
|
||||
Less: Allowance for doubtful accounts
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Raw materials
|
$
|
|
$
|
|
||||
Work in process
|
|
|
||||||
Finished goods
|
|
|
||||||
Total inventory
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Manufacturing equipment
|
$
|
|
$
|
|
||||
Office equipment
|
|
|
||||||
Transportation equipment
|
|
|
||||||
Leasehold improvement
|
|
|
||||||
Total cost
|
|
|
||||||
Less: Total accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
Construction in progress
|
|
|
||||||
Total property, plant and equipment, net
|
$
|
|
$
|
|
|
December 31,
|
|||||||
|
2021
|
2020
|
||||||
Land use right purchase amount
|
$
|
|
$
|
|
||||
Less: accumulated amortization
|
(
|
)
|
(
|
)
|
||||
Land use right, net
|
$
|
|
$
|
|
Year ending December 31,
|
||||
2022
|
|
|
||
2023
|
|
|||
2024
|
|
|||
2025
|
|
|||
2026
|
|
|
December 31,
|
|||||||
|
2021
|
2020
|
||||||
Prepayment for property - Lingang
|
$
|
|
$
|
|
||||
Prepayment for property, plant and equipment and other non-current assets |
||||||||
Prepayment for property - lease deposit |
||||||||
Security deposit for land use right
|
|
|
||||||
Others
|
|
|
||||||
Total other long-term assets
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Line of credit up to RMB
|
||||||||
1)due on April 1, 2021 with an annual interest rate of
|
$
|
|
$
|
|
||||
2)due on June 27, 2021 with an annual interest rate of
|
|
|
||||||
3)due on April 29, 2021 with an annual interest rate of
|
|
|
||||||
4)due on June 27, 2021 with an annual interest rate of
|
|
|
||||||
Line of credit up to RMB
|
||||||||
1)due on April 12, 2021 with an annual interest rate of
|
|
|
||||||
2)due on May 24, 2021 with an annual interest rate of
|
|
|
||||||
Line of credit up to RMB
|
||||||||
1)due on May 27, 2021 with an annual interest rate of
|
|
|
||||||
2)due on June 27, 2021 with an annual interest rate of
|
|
|
||||||
3)due on May 28, 2021 with an annual interest rate of
|
|
|
||||||
4)due on June 7, 2021 with an annual interest rate of
|
|
|
||||||
5)due on June 16, 2021 with an annual interest rate of
|
|
|
||||||
Line of credit up to RMB
|
||||||||
1)due on August 10,2021 with annual interest rate of
|
|
|
||||||
2)due on August 25,2021 with annual interest rate of
|
|
|
||||||
Line of credit up to RMB
|
||||||||
1)due on
|
|
|
||||||
Line of credit up to RMB
|
||||||||
1)due on
|
|
|||||||
Line of credit up to RMB
|
||||||||
1)due on
|
|
|||||||
Total
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Accrued commissions
|
$
|
|
$
|
|
||||
Accrued warranty
|
|
|
||||||
Accrued payroll
|
|
|
||||||
Accrued professional fees
|
|
|
||||||
Accrued machine testing fees
|
|
|
||||||
Others
|
|
|
||||||
Total
|
$
|
|
$
|
|
|
Year Ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019 | |||||||||
Operating lease cost
|
$
|
|
$
|
|
$ |
|||||||
Short-term lease cost
|
|
|
||||||||||
Lease cost
|
$
|
|
$
|
|
$ |
|
Year Ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019 |
|||||||||
Cash paid for amounts included in the measurement of lease liabilities:
|
||||||||||||
Operating cash outflow from operating leases
|
$
|
|
$
|
|
$ |
|
December 31,
|
|||
2022
|
$
|
|
||
2023
|
|
|||
2024
|
|
|||
2025
|
|
|||
Total lease payments
|
|
|||
Less: Interest
|
(
|
)
|
||
Present value of lease liabilities
|
$
|
|
|
December 31,
|
|||||||
|
2021
|
2020
|
||||||
Remaining lease term and discount rate:
|
||||||||
Weighted average remaining lease term (years)
|
|
|
||||||
Weighted average discount rate
|
|
%
|
|
%
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Loan from China Merchants Bank
|
$
|
|
$
|
|
||||
Loans from Bank of China | ||||||||
Less: Current portion
|
(
|
)
|
(
|
)
|
||||
$
|
|
$
|
|
Year ending December 31,
|
||||
2022
|
$
|
|
||
2023
|
|
|||
2024
|
|
|||
2025
|
|
|||
2026 and onwards
|
|
|||
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Subsidies to Stress Free Polishing project, commenced in 2008 and 2017
|
$
|
|
$
|
|
||||
Subsidies to Electro Copper Plating project, commenced in 2014
|
|
|
||||||
Subsidies to Polytetrafluoroethylene, commenced in 2018
|
|
|
||||||
Subsidies to Tahoe-Single Bench Clean, commenced in 2020
|
|
|
||||||
Subsidies to other cleaning tools,commenced in 2020
|
|
|
||||||
Subsidies to SW Lingang R&D development in 2021 | ||||||||
Other
|
|
|
||||||
Total
|
$
|
|
$
|
|
December 31,
|
||||||||
2021
|
2020
|
|||||||
Ninebell
|
$
|
|
$
|
|
||||
Shengyi
|
|
|
||||||
Hefei Shixi
|
|
|
||||||
Subtotal |
||||||||
Other investee: |
||||||||
Waferworks |
||||||||
Total
|
$
|
|
$
|
|
July 29,
2020
|
||||
Fair value of common share(1)
|
$
|
|
||
Expected term in years(2)
|
|
|||
Volatility(3)
|
|
%
|
||
Risk-free interest rate(4)
|
|
%
|
||
Expected dividend(5)
|
|
%
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(5) |
|
December 31,
|
||||||||
|
2021
|
2020
|
||||||
Trading securities listed in Shanghai Stock Exchange
|
||||||||
Cost
|
$
|
|
$
|
|
||||
Market value
|
$
|
|
$
|
|
December 31, |
||||||||
Prepaid expenses
|
2021
|
2020
|
||||||
Ninebell
|
$
|
|
$
|
|
December 31, |
||||||||
Accounts payable
|
2021
|
2020 | ||||||
Ninebell
|
$
|
|
$
|
|
||||
Shengyi
|
|
|
||||||
Total
|
$
|
|
$
|
|
Year Ended December 31
|
||||||||||||
Purchase of materials
|
2021
|
2020
|
2019
|
|||||||||
Ninebell
|
$
|
|
$
|
|
$
|
|
||||||
Shengyi
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
Year Ended December 31
|
||||||||||||
Service fee charged by
|
2021
|
2020
|
2019
|
|||||||||
Shengyi
|
$
|
|
$
|
|
$
|
|
||||||
Ninebell
|
|
|
|
|||||||||
Total
|
$ |
|
$ |
|
$ |
|
Balance at December 31, 2019
|
$
|
|
||
Net income attributable to redeemable non-controlling interests
|
|
|||
Effect of foreign currency translation gain attributable to redeemable non-controlling interests
|
(
|
)
|
||
Reclassification of redeemable non-controlling interest
|
(
|
)
|
||
Balance at December 31, 2020
|
$
|
|
|
Year Ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019
|
|||||||||
Stock-Based Compensation Expense:
|
||||||||||||
Cost of revenue
|
$
|
|
$
|
|
$
|
|
||||||
Sales and marketing expense
|
|
|
|
|||||||||
Research and development expense
|
|
|
|
|||||||||
General and administrative expense
|
|
|
|
|||||||||
|
$
|
|
$
|
|
$
|
|
|
Year Ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019
|
|||||||||
Stock-based compensation expense by type:
|
||||||||||||
Employee stock purchase plan
|
$
|
|
$
|
|
$
|
|
||||||
Non-employee stock purchase plan
|
|
|
|
|||||||||
Subsidiary option grants
|
|
|
|
|||||||||
|
$
|
|
$
|
|
$
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Fair value of common share(1)
|
$
|
|
$
|
|
$
|
|
||||||
Expected term in years(2)
|
|
|
|
|||||||||
Volatility(3)
|
|
%
|
|
%
|
|
%
|
||||||
Risk-free interest rate(4)
|
|
%
|
|
%
|
|
%
|
||||||
Expected dividend(5)
|
|
%
|
|
%
|
|
%
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(5) |
|
Year Ended
December 31,
|
||||
2020
|
||||
Fair value of common share(1)
|
$
|
|
||
Expected term in years(2)
|
|
|||
Volatility(3)
|
|
%
|
||
Risk-free interest rate(4)
|
|
%
|
||
Expected dividend(5)
|
%
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(5) |
|
Number of
Option Share
|
Weighted
Average Grant
Date Fair Value
|
Weighted
Average
Exercise
Price
|
Weighted Average
Remaining
Contractual Term
|
||||||||||
Outstanding at December 31, 2018
|
|
$
|
|
$
|
|
|
|||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Expired
|
(
|
)
|
|
|
|||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2019
|
|
|
|
|
|||||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2020
|
|
|
|
|
|||||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2021
|
|
$
|
|
$
|
|
|
|||||||
Vested and exercisable at December 31, 2021
|
|
Number of
Option Shares
|
Weighted
Average Grant
Date Fair Value
|
Weighted
Average
Exercise
Price
|
Weighted Average
Remaining
Contractual Term
|
||||||||||
Outstanding at December 31, 2018
|
|
$
|
|
$
|
|
||||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Expired
|
|
|
|
||||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2019
|
|
|
|
|
|||||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Expired
|
|
||||||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2020
|
|
|
|
|
|||||||||
Granted
|
|
|
|
||||||||||
Exercised
|
(
|
)
|
|
|
|||||||||
Expired
|
|
|
|
||||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2021
|
|
$
|
|
$
|
|
|
|||||||
Vested and exercisable at December 31, 2021
|
|
Number of
Option Shares in
ACM Shanghai
|
Weighted
Average Grant
Date Fair Value
|
Weighted
Average
Exercise
Price
|
Weighted Average
Remaining
Contractual Term
|
||||||||||
Outstanding at December 31, 2019
|
|
$
|
|
$
|
|
|
|||||||
Granted
|
|
|
|
||||||||||
Exercised
|
|
|
|
||||||||||
Expired
|
|
|
|
||||||||||
Forfeited/cancelled
|
(
|
)
|
|
|
|||||||||
Outstanding at December 31, 2020
|
|
$
|
|
$
|
|
|
|||||||
Granted | |||||||||||||
Exercised | |||||||||||||
Expired | |||||||||||||
Forfeited/cancelled | ( |
) | |||||||||||
Outstanding at December 31, 2021 | $ | $ | |||||||||||
Vested and exercisable at December 31, 2021
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
(in thousands) |
||||||||||||
Current:
|
||||||||||||
U.S. federal
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||
U.S. state
|
(
|
)
|
(
|
)
|
|
|||||||
Foreign
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total current tax expense
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Deferred:
|
||||||||||||
U.S. federal
|
|
|
|
|||||||||
U.S. state
|
|
|
|
|||||||||
Foreign
|
|
(
|
)
|
(
|
)
|
|||||||
Total deferred tax benefit
|
|
|
|
|||||||||
Total income tax benefit (expense)
|
$
|
(
|
)
|
$
|
|
$
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019 |
||||||||||
Deferred tax assets:
|
||||||||||||
Net operating loss carry forwards (offshore)
|
$
|
|
$
|
|
$ | |||||||
Net operating loss carry forwards (U.S.) and credit
|
|
|
||||||||||
Deferred revenue (offshore)
|
|
|
||||||||||
Accruals (U.S.)
|
|
|
||||||||||
Reserves and other (offshore)
|
|
|
||||||||||
Stock-based compensation (U.S.)
|
|
|
||||||||||
Property and equipment (U.S.)
|
|
|
||||||||||
Lease liability
|
|
|
||||||||||
Total gross deferred tax assets
|
|
|
||||||||||
Less: valuation allowance
|
(
|
)
|
(
|
)
|
( |
) | ||||||
Total deferred tax assets
|
|
|
||||||||||
Deferred tax liabilities:
|
||||||||||||
Fixed assets
|
(
|
)
|
(
|
)
|
||||||||
Deferred revenue (offshore)
|
(
|
)
|
(
|
)
|
||||||||
Unrealized gain on trading securities
|
|
(
|
)
|
|||||||||
Equity Investments
|
( |
) | ||||||||||
Total deferred tax liabilities
|
(
|
)
|
(
|
)
|
||||||||
Translation difference
|
|
|
||||||||||
Deferred tax assets, net
|
$
|
|
$
|
|
$ |
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Effective tax rate reconciliation:
|
||||||||||||
Income tax provision at statutory rate
|
|
%
|
|
%
|
|
%
|
||||||
Stock Compensation
|
( |
) | ( |
) | ( |
) | ||||||
Foreign rate differential
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Other permanent difference
|
(
|
)
|
|
|
||||||||
Foreign income taxed in US |
||||||||||||
Foreign Research Expense
|
( |
) | ( |
) | ( |
) | ||||||
Change in valuation allowance
|
|
(
|
)
|
(
|
)
|
|||||||
Total income tax expense (benefit)
|
|
%
|
(
|
)%
|
(
|
)%
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019 |
||||||||||
Beginning balance
|
$
|
|
$
|
|
$ | |||||||
Increase of unrecognized tax benefits taken in prior years
|
|
|
||||||||||
Increase of unrecognized tax benefits related to current year
|
|
|
||||||||||
Reductions for tax positions related to prior years |
( |
) | ||||||||||
Reductions to unrecognized tax benefits related to lapsing statute of limitations
|
|
|
||||||||||
Ending balance
|
$
|
|
$
|
|
$ |
December 31,
|
||||||||
2021
|
2020
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Accounts receivable
|
|
|||||||
Due from intercompany
|
|
|
||||||
Other receivable
|
|
|
||||||
Prepaid expenses
|
|
|
||||||
Total current assets
|
|
|
||||||
Deferred tax assets
|
|
|
||||||
Investment in unconsolidated subsidiaries
|
|
|
||||||
Total assets
|
|
|
||||||
Liabilities and Stockholders’ Equity
|
||||||||
Accounts payable
|
|
|
||||||
Other payable
|
|
|
||||||
Income taxes payable
|
|
|
||||||
FIN-48 payable
|
|
|
||||||
Deferred tax liability
|
|
|
||||||
Total liabilities
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders equity
|
$
|
|
$
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
||||||
Cost of revenue
|
|
(
|
)
|
(
|
)
|
|||||||
Gross profit
|
|
|
|
|||||||||
Operating expenses:
|
||||||||||||
Sales and marketing expenses
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
General and administrative expenses
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Research and development expenses
|
|
|
(
|
)
|
||||||||
Loss from operations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Equity in earnings of unconsolidated subsidiaries
|
|
|
|
|||||||||
Change in fair value of financial liability
|
|
(
|
)
|
|
||||||||
Interest income, net
|
|
|
|
|||||||||
Interest expense, net
|
|
|
(
|
)
|
||||||||
Other income, net
|
|
|
|
|||||||||
Income before income taxes
|
|
|
|
|||||||||
Income tax expense
|
|
|
|
|||||||||
Net income
|
$
|
|
$
|
|
$
|
|
Year Ended December 31,
|
||||||||||||
2021
|
2020
|
2019
|
||||||||||
Net cash used in operating activities
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Net cash provided by investing activities
|
|
|
|
|||||||||
Net cash provided by financing activities
|
|
|
|
|||||||||
Net increase (decrease) in cash and cash equivalents
|
(
|
)
|
|
|
||||||||
Cash and cash equivalents, beginning of year
|
|
|
|
|||||||||
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(
|
)
|
||||||||
Cash and cash equivalents, end of year
|
$
|
|
$
|
|
$
|
|
Item 9A. |
Controls and Procedures
|
● |
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our company;
|
● |
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of our company are being made only in accordance with authorizations of management and directors of our company; and
|
● |
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our company’s assets that could have a material effect on the financial statements.
|
Item 10. |
Directors, Executive Officers and Corporate Governance
|
Item 11. |
Executive Compensation
|
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Item 13. |
Certain Relationships and Related Transactions, and Director Independence
|
Item 14. |
Principal Accounting Fees and Services
|
Item 15. |
Exhibits and Financial Statement Schedules
|
(b) |
Exhibits.
|
Exhibit
No.
|
Description
|
|
Restated Certificate of Incorporation of ACM Research, Inc. (incorporated herein by reference to Exhibit 3.01 to the Current Report on Form 8-K filed on
November 14, 2017)
|
||
Certificate of Amendment to Restated Certificate of Incorporation of ACM Research, Inc., dated July 13, 2021 (incorporated herein by reference to Exhibit
3.01 to the Current Report filed on July 13, 2021)
|
||
Restated Bylaws of ACM Research, Inc. (incorporated herein by reference to Exhibit 3.02 to the Current Report on Form 8-K filed on November 14, 2017)
|
||
Senior Secured Promissory Note dated March 30, 2018 issued by Shengxin (Shanghai) Management Consulting Limited Partnership to ACM Research (Shanghai),
Inc. (incorporated herein by reference to Exhibit 10.03 to the Quarterly Report on Form 10-Q filed on May 14, 2018)
|
||
Intercompany Promissory Note dated March 30, 2018 issued by ACM Research (Shanghai), Inc. to ACM Research, Inc. (incorporated herein by reference to
Exhibit 10.04 to the Quarterly Report on Form 10-Q filed on May 14, 2018)
|
||
Warrant Exercise Agreement dated March 30, 2018 by and among ACM Research, Inc., ACM Research (Shanghai), Inc., and Shengxin (Shanghai) Management
Consulting Limited Partnership (incorporated herein by reference to Exhibit 10.02 to the Quarterly Report on Form 10-Q filed on May 14, 2018)
|
||
Warrant to Purchase Class A Common Stock issued to Shengxin (Shanghai) Management Consulting Limited Partnership dated July 29, 2020 (incorporated herein
by reference to Exhibit 4.01 to the Quarterly Report on Form 10-Q filed on August 10, 2020)
|
||
Description of ACM Research, Inc.’s Securities
|
||
Lease dated March 22, 2017 between ACM Research, Inc. and D&J Construction, Inc. (incorporated herein by reference to Exhibit 10.01 to the
Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Lease Amendment dated February 28, 2018 between ACM Research, Inc. and D&J Construction, Inc. (incorporated herein by reference to Exhibit 10.06 to
the Amended Quarterly Report on Form 10-Q/A filed on October 15, 2018)
|
||
Lease Amendment dated February 4, 2019 between ACM Research, Inc. and D&J Construction, Inc. (incorporated herein by reference to Exhibit 10.1 to the
Current Report on Form 8-K filed on February 8, 2019)
|
||
Lease Amendment dated January 4, 2021 between ACM Research, Inc. and D&J Construction, Inc.
|
||
Lease Agreement dated April 26, 2018 between ACM Research (Shanghai), Inc. and Shanghai Zhangjiang Group Co., Ltd. (incorporated herein by reference to
Exhibit 10.01 to the Amended Quarterly Report on Form 10-Q/A filed on October 15, 2018)
|
||
Lease Agreement dated January 18, 2018 between ACM Research (Shanghai), Inc. and Shanghai Shengyu Culture Development Co., Ltd. (incorporated herein by
reference to Exhibit 10.05 to the Amended Quarterly Report on Form 10-Q/A filed on October 15, 2018)
|
||
Securities Purchase Agreement dated March 14, 2017 by and among ACM Research, Inc., Shengxin (Shanghai) Management Consulting Limited Partnership and ACM
Research (Shanghai), Inc. (incorporated herein by reference to Exhibit 10.03 to the Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Securities Purchase Agreement dated March 23, 2017 between ACM Research, Inc. and Shanghai Science and Technology Venture Capital Co., Ltd., as amended
(incorporated herein by reference to Exhibit 10.04 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
||
Ordinary Share Purchase Agreement dated September 6, 2017 by and among ACM Research, Inc., Ninebell Co., Ltd. and Moon-Soo Choi (incorporated herein by
reference to Exhibit 10.07 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
Form of Second Amended and Restated Registration Rights Agreement to be entered into between ACM Research, Inc. and certain of its stockholders
(incorporated herein by reference to Exhibit 10.09 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
||
Stock Purchase Agreement, dated October 11, 2017, by and among ACM Research, Inc., Xunxin (Shanghai) Capital Co., Limited, Xinxin (Hongkong) Capital Co.,
Limited and David H. Wang (incorporated herein by reference to Exhibit 10.10 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
||
Nomination and Voting Agreement, dated October 11, 2017, by and among Xinxin (Hongkong) Capital Co., Limited, ACM Research, Inc., David H. Wang, and the
individuals named therein (incorporated herein by reference to Exhibit 10.12 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
||
Termination Agreement between ACM Research, Inc. and Xinxin (Hongkong) Capital Co., Limited, dated as of May 18, 2021 (incorporated herein by reference
to Exhibit 10.01 to the Current Report on Form 8-K filed on May 21, 2021)
|
||
Voting Agreement, dated March 23, 2017, by and among Shanghai Technology Venture Capital Co., Ltd. (also known as Shanghai Science and Technology Venture
Capital Co., Ltd.) and ACM Research, Inc. (incorporated herein by reference to Exhibit 10.13 to the Amended Registration Statement on Form S-1/A filed on October 18, 2017)
|
||
Form of Capital Increase Agreement between ACM Research, Inc. and certain investors (incorporated herein by reference to Exhibit 10.01 to the Quarterly
Report on Form 10-Q filed on August 12, 2019)
|
||
Schedule identifying agreements substantially identical to the form of Capital Increase Agreement filed as Exhibit 10.12 hereto (incorporated herein by
reference to Exhibit 10.01(a) to the Quarterly Report on Form 10-Q filed on August 12, 2019)
|
||
Form of Agreement between ACM Research, Inc. and certain Investors (incorporated herein by reference to Exhibit 10.02 to the Quarterly Report on Form
10-Q filed on August 12, 2019)
|
||
Schedule identifying agreements substantially identical to the form of Agreement filed as Exhibit 10.13 hereto (incorporated herein by reference to
Exhibit 10.02(a) to the Quarterly Report on Form 10-Q filed on August 12, 2019)
|
||
Partnership Agreement of Hefei Shixi Chanheng Integrated Circuit Industry Venture Capital Fund Partnership (LP) dated September 5, 2019 by and among
Infotech National Emerging Industry Venture Investment Guidance Fund (LP), Hefei Guozheng Asset Management Co, Ltd., Hefei Economic and Technological Development Zone Industrial Investment Guidance Fund Co., Ltd., ACM Research (Shanghai),
Inc., Hefei Tongyi Equity Investment Partnership (LP), Shenzen Waitan Technology Development Co., Ltd., and Beijing Shixi Qingliu Investment Co., Ltd. (incorporated herein by reference to Exhibit 10.03 to the Quarterly Report on Form 10-Q
filed on November 13, 2019)
|
||
2016 Omnibus Incentive Plan of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.01 to the Quarterly Report on Form 10-Q filed on
December 8, 2017)
|
||
Form of Incentive Stock Option Grant Notice and Agreement under 2016 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.10(a) to the
Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Form of Non-qualified Stock Option Grant Notice and Agreement under 2016 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.10(b) to
the Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Form of Restricted Stock Unit Grant Notice and Agreement under 2016 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.10(c) to the
Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Form of Nonstatutory Stock Option Agreement of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.11 to the Registration Statement on
Form S-1 filed on September 13, 2017)
|
||
1998 Stock Option Plan of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed on
September 13, 2017)
|
||
Form of Incentive Stock Option Agreement under 1998 Stock Option Plan (incorporated herein by reference to Exhibit 10.12(a) to the Registration
Statement on Form S-1 filed on September 13, 2017)
|
||
Form of Non-statutory Stock Option Agreement under 1998 Stock Option Plan (incorporated herein by reference to Exhibit 10.12(b) to the Registration
Statement on Form S-1 filed on September 13, 2017)
|
Form of Indemnification Agreement entered into between ACM Research, Inc. and certain of its directors and officers (incorporated herein by reference to
Exhibit 10.13 to the Registration Statement on Form S-1 filed on September 13, 2017)
|
||
Letter agreement dated June 12, 2019 between ACM Research, Inc. and Mark McKechnie (incorporated herein by reference to Exhibit 10.02 to the Current
Report on Form 8-K filed on August 13, 2019)
|
||
Employment Agreement dated January 8, 2018 between ACM Research (Shanghai), Inc and Lisa Feng
|
||
Note Assignment and Cancellation Agreement dated April 30, 2020 by and among ACM Research, Inc., ACM Research (Shanghai), Inc. and Shengxin (Shanghai)
Management Consulting Limited Partnership (incorporated herein by reference to Exhibit 10.02 to the Quarterly Report Form 10-Q filed on May 8, 2020)
|
||
Share Transfer and Note Cancellation Agreement dated April 30, 2020 between ACM Research, Inc. and Shengxin (Shanghai) Management Consulting Limited
Partnership (incorporated herein by reference to Exhibit 10.03 to the Quarterly Report on Form 10-Q filed on May 8, 2020)
|
||
Amendment No. 1 to Share Transfer and Note Cancellation Agreement dated July 29, 2020 between ACM Research, Inc. and Shengxin (Shanghai) Management
Consulting Limited Partnership (incorporated herein by reference to Exhibit 10.01 to the Quarterly Report on Form 10-Q filed on November 9, 2020)
|
||
Grant Contract for State-owned Construction Land Use Right in Shanghai City (Category of R&D Headquarters and Industrial Projects) dated as of May 7,
2020 between ACM Research (Lingang), Inc. and China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration (incorporated herein by reference to Exhibit 10.01 to the Current Report on Form 8-K filed on May 13, 2020)
|
||
Commitment Letter Regarding the Lock-up of Shares, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.01
to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Shareholding Intent and Intent to Reduce Shareholding, effective as of May 26, 2020, of ACM Research, Inc. and David H. Wang
(incorporated herein by reference to Exhibit 10.02 to the Current Report to Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding the Plan and Binding Measures for Stabilizing the Stock Price of ACM Research (Shanghai), Inc. Within Three Years After
Listing, effective as of May 26, 2020, of ACM Research, Inc., ACM Research (Shanghai), Inc., and certain individuals named therein (incorporated herein by reference to Exhibit 10.03 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Fraudulent Issuance of Listed Shares, effective as of May 26, 2020, of ACM Research, Inc., ACM Research (Shanghai), Inc. and
David H. Wang (incorporated herein by reference to Exhibit 10.04 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding the Lack of False Records, Misleading Statements or Major Omissions in the Preliminary Information Document, effective as of
May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.05 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Making Up for Diluted Immediate Returns, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by
reference to Exhibit 10.06 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Unfulfilled Commitment on Binding Measures, effective as of May 26, 2020, of ACM Research, Inc. and David H. Wang
(incorporated herein by reference to Exhibit 10.07 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding the Avoidance of Competition in the Same Industry, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein
by reference to Exhibit 10.08 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding the Standardization and Reduction of Related Transactions, effective as of May 26, 2020, of ACM Research, Inc. (incorporated
herein by reference to Exhibit 10.09 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding the Avoidance of Funds Occupation and Illegal Guarantee, effective as of May 26, 2020, of ACM Research, Inc. (incorporated
herein by reference to Exhibit 10.10 to the Current Report on Form 8-K filed on June 1, 2020)
|
Statement and Commitment Letter, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.11 to the Current
Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Property Lease Matters, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit
10.12 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Social Insurance and Housing Provident Fund Matters, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein
by reference to Exhibit 10.13 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Commitment Letter Regarding Foreign Exchange Matters, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit
10.14 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Confirmation and Commitment Letter Regarding the Historical Evolution Related Matters Regarding ACM Research (Shanghai), Inc., effective as of May 26,
2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.15 to the Current Report on Form 8-K filed on June 1, 2020)
|
||
Confirmation Letter, effective as of May 26, 2020, of ACM Research, Inc. (incorporated herein by reference to Exhibit 10.16 to the Current Report on Form
8-K filed on June 1, 2020)
|
||
Qingdao Fortune-Tech Xinxing Capital Partnership (L.P.) Partnership Agreement, dated June 9, 2020, among China Fortune Tech Capital Co., Ltd., as general
partner, and the several limited partners named therein, including ACM Research (Shanghai), Inc. (incorporated herein by reference to Exhibit 10.01 to the Current Report on Form 8-K filed on July 7, 2020)
|
||
Supplementary Agreement to Partnership Agreement of Qingdao Fortune-Tech Xinxing Capital Partnership (L.P.), dated June 15, 2020, among China Fortune
Tech Capital Co., Ltd., as general partner, and the several limited partners named therein, including ACM Research (Shanghai), Inc. (incorporated herein by reference to Exhibit 10.02 to the Current Report on Form 8-K filed on July 7,
2020)
|
||
Adoption Agreement dated July 29, 2020 between ACM Research, Inc. and Shengxin (Shanghai) Management Consulting Limited Partnership (amending the Second
Amended and Restated Registration Rights Agreement between ACM Research, Inc. and certain of its stockholders filed with the SEC on October 18, 2017 as Exhibit 10.09 to Amendment No. 1 to Registration Statement on Form S-1) (incorporated
herein by reference to Exhibit 10.02 to the Quarterly Report on Form 10-Q filed on November 9, 2020)
|
||
Form of Shanghai Public Rental Housing Overall Pre-Sale Contract (incorporated herein by reference to Exhibit 10.01 to the Current Report on Form 8-K filed on February 25,
2021)
|
||
Schedule identifying agreements substantially identical to the form of Shanghai Public Rental Housing Overall Pre-Sale Contract filed as Exhibit 10.43
hereto (incorporated herein by reference to Exhibit 10.01(a) to the Current Report on Form 8-K filed on February 25, 2021)
|
||
Loan and Mortgage Contract dated November 19, 2020 between China Merchants Bank Co., Ltd., Shanghai Pilot Free Trade Zone Lin-Gang Special Area
Sub-branch and Shengwei Research (Shanghai), Inc. (incorporated herein by reference to Exhibit 10.02 to the Current Report on Form 8-K filed on February 25, 2021)
|
||
Irrevocable Letter of Guarantee dated November 19, 2020 between China Merchants Bank Co., Ltd., Shanghai Pilot Free Trade Zone Lin-Gang Special Area
Sub-branch and ACM Research (Shanghai), Inc. (incorporated herein by reference to Exhibit 10.03 to the Current Report on Form 8-K filed on February 25, 2021)
|
||
Plant lease Contract dated as of February 1, 2021 between ACM Research (Shanghai), Inc. and Shanghai Shengyu Culture Development Co., Ltd. (incorporated
herein by reference to Exhibit 10.01 to the Quarterly Report on Form 10-Q filed on May 7, 2021)
|
||
List of Subsidiaries of ACM Research, Inc.
|
||
Consent of BDO China Shu Lan Pan Certified Public Accountants LLP
|
||
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
|
||
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
|
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
|
||
101.INS
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document)
|
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)
|
+ |
Indicates management contract or compensatory plan.
|
‡ |
Certain information in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]
|
† |
Unofficial English translation of original document prepared in Mandarin Chinese.
|
* |
Certain appendices have been omitted pursuant to Item 601(a)(5) of Regulation S-K. We hereby undertake to furnish copies of the omitted appendices upon request by the
Securities and Exchange Commission, provided that we may request confidential treatment pursuant to Rule 24b‑2 of the Securities Exchange Act of 1934 for the appendices so furnished.
|
ACM RESEARCH, INC.
|
||
By:
|
/s/ David H. Wang
|
|
David H. Wang
|
||
Chief Executive Officer and President
|
Signature
|
Title
|
|
/s/ David H. Wang
|
||
David H. Wang
|
Chief Executive Officer, President and Director
(Principal Executive Officer)
|
|
/s/ Mark A. McKechnie
|
||
Mark A. McKechnie
|
Chief Financial Officer, Executive Vice President and Treasurer
(Principal Financial and Accounting Officer)
|
|
/s/ Haiping Dun
|
||
Haiping Dun
|
Director
|
|
/s/ Chenming Hu
|
||
Chenming Hu
|
Director
|
|
/s/ Tracy Liu
|
||
Tracy Liu
|
Director
|
|
/s/ Yinan Xiang
|
||
Yinan Xiang
|
Director
|
• |
the transaction is approved by the board of directors prior to the time that the interested stockholder became an interested stockholder;
|
• |
upon consummation of the transaction, which resulted in the stockholder’s becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding stock owned by directors who are also officers of the corporation; or
|
• |
subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the board and authorized at an
annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
• |
Separate Class B Vote for Certain Transactions.
Until the first date on which the outstanding shares of Class B common stock represent less than 35% of the combined voting power of common stock, any transaction that would result in a change in control of our company will require the
approval of a majority of our outstanding Class B common stock voting as a separate class. This provision could delay or prevent the approval of a change in control that might otherwise be approved by a majority of outstanding shares of
Class A and Class B common stock, voting together on a combined basis.
|
• |
Dual Class Stock. As described above in
“—Common Stock—Voting Rights” above, our charter provides for a dual class common stock structure, which provides certain members of our senior management with the ability to control the outcome of matters requiring stockholder approval,
even if they collectively own significantly less than a majority of the shares of our outstanding Class A and Class B common stock, including the election of directors and significant corporate transactions, such as a merger or other sale
of our company or its assets.
|
• |
Supermajority Approvals. Our charter and
bylaws provide that when the outstanding shares of Class B common stock represent less than a majority of the combined voting power of common stock, certain amendments to our charter or bylaws will require the approval of two-thirds of the
combined vote of our then-outstanding shares of Class A and Class B common stock. This will have the effect of making it more difficult to amend our charter or bylaws to remove or modify certain provisions.
|
• |
Board of Directors Vacancies. Our charter and
bylaws provide that stockholders may fill vacant directorships. When the outstanding shares of Class B common stock represent less than a majority of the combined voting power of common stock, our charter and bylaws authorize only the board
of directors to fill vacant directorships. In addition, the number of directors constituting the board is set only by resolution adopted by a majority vote of our entire board. These provisions restricting the filling of vacancies will
prevent a stockholder from increasing the size of the board and gaining control of the board by filling the resulting vacancies with its own nominees. Our charter provides that directors may be removed with or without cause only by the
affirmative vote of the holders of at least two-thirds of the votes that all of the stockholders would be entitled to cast in any annual election of directors.
|
• |
Classified Board. The board of directors is
not currently classified. Our charter and bylaws provide that when outstanding shares of Class B common stock represent less than a majority of the combined voting power of common stock, the board will be classified into three classes of
directors, each of which will hold office for a three-year term. In addition, thereafter, directors may be removed from the board with or without cause only by the affirmative vote of the holders of at least two-thirds of the voting power
of the then-outstanding shares of Class A and Class B common stock. The existence of a classified board could delay a successful tender offeror from obtaining majority control of the board, and the prospect of that delay might deter a
potential offeror.
|
• |
Stockholder Action; Special Meeting of Stockholders.
Our charter provides that stockholders will be able to take action by written consent. When the outstanding shares of Class B common stock represent less than a majority of the combined voting power of common stock, our stockholders will no
longer be able to take action by written consent, and will only be able to take action at annual or special meetings of our stockholders. Stockholders will not be permitted to cumulate their votes for the election of directors. The absence
of cumulative voting may make it more difficult for stockholders who own less than a majority in voting power to elect any directors to the board of directors. Our bylaws further provide that special meetings of our stockholders may be
called only by the board, the chair of the board or our chief executive officer. A stockholder may not call a special meeting, which may delay the ability of our stockholders to force consideration of a proposal or for holders controlling a
majority in voting power of our capital stock to take any action, including the removal of director.
|
• |
Advance Notice Requirements for Stockholder Proposals
and Director Nominations. Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at any meeting of
stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from
making nominations for directors at our meetings of stockholders.
|
• |
Issuance of Undesignated Preferred Stock. The
board of directors has the authority, without further action by the stockholders, to issue shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the board. The existence
of authorized but unissued shares of preferred stock enables the board to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.
|
RE:
|
Expiration of Lease at 42307 Osgood Rd., Unit I, Fremont, CA
|
/s/ Tammy Eliseian
|
|
Tammy Eliseian |
|
President |
|
/s/ Lillian Chen
|
|
Lillian Chen
|
|
Procurement and Office Manager
|
|
ACM Research, Inc.
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
1
|
GENERAL PROVISIONS总则
|
2 |
TERM (Termination during probationary period, renewal, and termination) 协议
|
3
|
Employee Obligation & Responsibility 员工的义务与职责
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
4
|
REMUNERATION AND BENEFITS 报酬和待遇
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
5
|
EMPLOYEE'S GENERAL OBLIGATIONS员工的总体职责
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
6
|
TRAINING培训
|
盛美半导体设备(上海)有限公司
|
7
|
END AND TERMINATION OF THIS AGREEMENT 协议的终止与解除
|
盛美半导体设备(上海)有限公司
|
8
|
STATEMENT OF DISPUTE争议的条件
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
盛美半导体设备(上海)有限公司
|
Name of Subsidiary
|
|
Jurisdiction of Incorporation or Organization
|
ACM Research (Shanghai), Inc.
|
|
People’s Republic of China
|
CleanChip Technologies Limited
|
|
Hong Kong
|
ACM Research (Wuxi), Inc.
|
|
People’s Republic of China
|
ACM Research Korea CO., LTD.
|
|
Republic of Korea
|
Shengwei Research (Shanghai), Inc.
|
People’s Republic of China
|
|
ACM Research (Singapore) PTE, Ltd.
|
Singapore
|
|
ACM Research (CA), Inc.
|
United States of America
|
|
ACM Research (Cayman), Inc.
|
Cayman Islands
|
Date: March 1, 2022
|
/s/ David H. Wang
|
David H. Wang
|
|
Chief Executive Officer and President
|
|
(Principal Executive Officer)
|
Date: March 1, 2022
|
/s/ Mark A. McKechnie
|
Mark A. McKechnie
|
|
Chief Financial Officer, Executive Vice President and Treasurer
|
|
(Principal Financial Officer)
|
Date: March 1, 2022
|
/s/ David H. Wang
|
David H. Wang
|
|
Chief Executive Officer and President
|
|
(Principal Executive Officer)
|
Date: March 1, 2022
|
/s/ Mark A. McKechnie
|
Mark A. McKechnie
|
|
Chief Financial Officer, Executive Vice President and Treasurer
|
|
(Principal Financial Officer)
|